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Characterizing the drug resistance mutations that have evolved in Mycobacterium 
tuberculosis (Mtb), has important implications for control of tuberculosis (TB) disease, 
through more accurate and timely use of therapy. Whole genome sequencing of Mtb 
can assist this characterization by providing insights into loci and specific mutations 
underlying drug resistance and the transmission success that enables their spread.  
 
We hypothesised that genetic variation outside of known resistance-conferring 
mutations might give additional information concerning drug resistance and fitness. 
Firstly, we explored the effect of lineage on the identification of drug resistance 
associations, applying novel lineage level genome-wide association study (GWAS) and 
convergence-based (PhyC) methods to drug resistance phenotypes of a global dataset 
of Mtb lineages 2 and 4. We identified known drug resistance variants and novel 
associations, uniquely identifying associations for lineage-specific GWAS analyses and 
reporting 17 novel associations between antimicrobial resistance phenotypes and Mtb 
genomic variants, demonstrating the utility of lineage-specific GWAS. 
 
To further examine the genomic basis of extensively drug resistant (XDR)-TB, we next 
applied the GWAS and PhyC techniques to a global dataset of 18,255 Mtb isolates. 
Through GWAS we identified 20 loci in novel associations within highly drug-resistant 
Mtb strains. Cluster-based GWAS and a lack of overlap with associations identified 
through convergent-evolution-based analyses confirmed that many such associations 
have been driven by transmission in outbreaks of XDR-TB.  
 
We then investigated the feasibility of applying a learning classifier system to this 
dataset to predict rifampicin resistance and discover candidate loci for novel 
involvement, finally enabling a sensitivity of 93.7% and a specificity of 94.8% of 
rifampicin resistance prediction.  
 
Finally, we applied this methodology to the XDR phenotype in lineages 2 and 4 of a 
global dataset (n=13,270), achieving high accuracy of prediction and identifying a 




I wish to thank; 
My supervisors Martin Hibberd and Taane Clark. 
The members of the group including Jody, Ernest, Matt R, Ben, Neneh, Matt H, Pepita, 
Dan, Amy, Gary and Anna.  
Colleagues who have helped me throughout my studies; Francesc Coll, Stéphane Hué 
and Sonal Shah. 
BBSRC and the LiDo team for continued support. 
My mother, Annette. 
My father, Kofi. 
My brother, Kwabena. 
My Nana, Christine. 






Table of Contents 
Acknowledgements ................................................................................................... 6 
Table of Contents ....................................................................................................... 7 
Abbreviation List ........................................................................................................ 9 
Introduction ............................................................................................................. 10 
Tuberculosis Disease ........................................................................................................ 11 
Global Tuberculosis Disease Burden ................................................................................................. 11 
Global Diversity of Mtb ..................................................................................................................... 11 
Tuberculosis Disease Aetiology ........................................................................................................ 12 
Vaccines ............................................................................................................................................ 13 
Treatment and the Evolution of Resistance ..................................................................................... 14 
Diagnosis and Surveillance ............................................................................................................... 15 
Genomics of Drug Resistance ........................................................................................................... 15 
Whole Genome Sequencing ............................................................................................................. 16 
Genome-Wide Discovery Methods ................................................................................... 17 
Genome Wide Association ............................................................................................................... 17 
Convergence-Based Methods ........................................................................................................... 19 
Application of Machine Learning ...................................................................................................... 20 
Data .................................................................................................................................................. 21 
Project Overview ............................................................................................................. 23 
References ....................................................................................................................... 24 
Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals 
lineage- specific associations with drug resistance ................................................... 35 
Genome-wide analyses identify novel associations with Extensively Drug Resistant 
tuberculosis ............................................................................................................. 64 
 8 
Genome-wide machine learning classifier applied to Mycobacterium tuberculosis as a 
novel approach to unravel genomic complexity associated with drug resistance .... 125 
Figure 1 ........................................................................................................................................... 148 
Figure 3 ........................................................................................................................................... 150 
Figure 4 ........................................................................................................................................... 151 
Supplementary Figure 2 ................................................................................................................. 153 
Supplementary Figure 3 ................................................................................................................. 154 
Table 1 ............................................................................................................................................ 156 
Supplementary Table 1 ................................................................................................................... 165 
Supplementary Table 2 ................................................................................................................... 166 
 Genome-wide Learning Classifier System applied to Extensively Drug Resistant 
Mycobacterium tuberculosis discovers novel resistance mechanisms ..................... 167 
Figure 1 ........................................................................................................................................... 184 
Figure 2 ........................................................................................................................................... 185 
Supplementary Figure 1 ................................................................................................................. 187 
Table 2 ............................................................................................................................................ 190 
Table 3 ............................................................................................................................................ 238 
Supplementary Table 1 ................................................................................................................... 287 
 Discussion and Conclusions ................................................................................... 288 
Discussion .............................................................................................................. 289 
Methodological Insights ................................................................................................. 289 
Biological Insights .......................................................................................................... 291 
Implications for Surveillance, Treatment and Diagnosis ................................................. 292 
Future Avenues of Work ................................................................................................ 293 
Conclusions .................................................................................................................... 294 




GWAS Genome-wide association analysis 
HLA Human leukocyte antigen 
Indel Insertion/deletion 
LCS Learning classifier system 
MIC Minimum Inhibitory Concentration 
Mtb Mycobacterium tuberculosis 
MDR Multidrug resistant 
NGS Next Generation Sequencing 
PCA Principal component analysis 
SNP Single Nucleotide Polymorphism 
SVM Support vector machine 
WGS Whole genome sequencing 



















Global Tuberculosis Disease Burden 
With an estimated 10.0 million people developing tuberculosis (TB) in 2017 and an 
estimated 1.6 million deaths [1], the global burden of TB is overwhelming. Worldwide, 
it is estimated that between 1.7 billion individuals are infected with the causative 
agent, Mycobacterium tuberculosis (Mtb), with 5-10% of those infected developing 
active disease [1].  There is great variation in the distribution of tuberculosis disease 
globally. Of those who developed TB in 2017, two thirds were in eight countries; India, 
China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa [1]. 
Most high income countries had less than 10 new cases per 100,000 population, whilst 
there were more than 500 cases per 100,000 population in countries such as 
Mozambique, the Philippines and South Africa [1]. 
 
Global Diversity of Mtb 
Mtb is a member of a larger group of related species, known as the Mtb 
complex. Today, Mtb has seven lineages, defined on the basis of molecular typing, 
which are endemic in different locations around the globe, with some persisting in 
geographical regions (lineages 5 and 6 in West Africa) and others across continents 
(lineage 2- East Asian/Beijing strains or lineage 4 – Euro-American strains) leading to 
the hypothesis that the strain-types are specifically adapted to people of different 
genetic backgrounds [2]. These lineages may vary in propensity to transmit, virulence, 
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site of infection and ultimately propensity to cause disease [3–5] but results are 
inconsistent and there is considerable inter-strain variation within lineages [6, 7]. 
Recent research into lineage 4 alludes to this variation, suggesting different 
evolutionary strategies are employed by different sublineages [8]. A set of single 
nucleotide polymorphisms (SNPs) has been identified that can be used to barcode sub-
lineages [9], leading to informatic tools that position sequenced samples within a 
global phylogeny [10].  
This global distribution of modern Mtb lineages is thought to be explained by 
their distribution through human migration and evolution resulting from changes in 
selection pressure as human populations underwent increases in population density or 
neutral evolution [5, 11–14]. 
 
Tuberculosis Disease Aetiology 
Under the classical model of TB, upon infection by Mtb there are three possible 
outcomes; clearance, latent disease or active disease. Transmission occurs during 
active disease due to the release of Mtb bacteria from the lungs in aerosol form. 
Inhalation of the Mtb bacterium can then result in macrophage infection within the 
lungs, invoking an immune response; macrophages likely phagocytose the bacteria, 
which are then resistant to macrophage killing mechanisms. 
The primary site of interaction between host and Mtb is the granuloma; which 
forms as a result of host immune response. Latent disease occurs when the granuloma 
successfully contains the Mtb infection. This is an active and complex process and lack 
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of containment allows dissemination of Mtb and progression to active TB disease [15–
17]. This granuloma diversity may impact in disease progression and outcomes; there is 
evidence that there is a spectrum of latent disease [18] and that reactivation risk is 
granuloma specific, with the potential of Mtb dissemination from only one or a few 
granuloma to cause active disease [19, 20].  
A number of reasons have been put forward to explain host heterogeneity in 
response to Mtb infection including; environmental host factors such as nutrition or 
HIV+ status, resulting in immunosuppression, Mtb genetics and host genetics. Indeed, a 
number of studies have found associations between human ethnicity and Mtb 
populations [2, 21], and additionally human ethnicity and M. africanum populations 
[22]. Such findings have led to suggestions of population specific adaptations in Mtb 
and host-pathogen coevolution [5]. Furthermore, ethnicity has been implicated in 
clinical TB phenotype [23].  
 
Vaccines 
Attenuated Mycobacterium bovis strain bacillus Callmette Guerin (BCG) has 
been used as a vaccine against TB since 1921. BCG shows variable efficacy [24], with 
factors such as previous exposure to non-tuberculous mycobacteria, human genetic 
variation and genetic variation of the vaccine strain itself potentially implicated  [25]. 
There remains a need for a new vaccine with increased efficacy [26]. 
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Treatment and the Evolution of Resistance 
Regardless of the initial emergence of Mtb, the widespread use and misuse of chemical 
antimicrobials since the 1960s likely represents a major new selection pressure 
governing Mtb evolution. Indeed, the emergence of drug resistance in Mtb is 
threatening disease control efforts. The evolution of drug resistance has occurred, 
despite clonal reproduction and a lack of lateral gene transfer in Mtb. Mtb resistance 
has developed to all anti-Mtb drugs, usually relatively shortly after their introduction 
and now isolates occur with multiple different drug resistances. 
Drug-resistant TB is phenotypically categorised as singly resistant to any anti-
Mtb drug, multi-drug resistant (MDR), resistance to two first–line treatments, 
rifampicin and isoniazid; extensively drug-resistant (XDR), defined as MDR alongside 
resistance to fluoroquinolones and at least one second-line injectable; or totally drug-
resistant (TDR or XXDR). In 2017, MDR TB amounted to 3.5% of new TB cases globally 
and 8.5% of these were XDR [1]. Treatment success rates for MDR and XDR TB are only 
55% and 34%, respectively [1]. 
 Two new drugs, bedaquiline and delaminid, have recently been introduced, but 
there remains a need for further development of new drugs and drug regimens, 
alongside increased drug susceptibility testing, better diagnosis and easier access to 
continued treatment [1]. 
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Diagnosis and Surveillance 
Currently culture-based assays are the standard for diagnosis and drug susceptibility 
testing of clinical Mtb isolates. Due to the slow growth of Mtb, this process is time 
consuming. For simplicity and speed, determining drug susceptibility is routinely done 
using agreed standardised cut-offs, resulting in the binary resistant or susceptible 
phenotype. However, these thresholds are subject to change over time and do not 
reflect the full diversity of the drug resistant phenotype. Additionally, it is possible to 
measure the minimum inhibitory concentration (MIC) required to prevent growth of 
an Mtb isolate, generating a more accurate continuous variable. Not only would this 
help to improve appropriate drug use for patients, but this data would greatly increase 
the information on determining the genetics of the drug resistance.  
Rapid molecular tests offer an interesting alternative to standard drug 
susceptibility testing, such as XPERT MTB/RIF, which is PCR-based and is able to 
diagnose tuberculosis alongside resistance to rifampicin, as well as new methods 
showing promise as point of care tests [27]. 
 
Genomics of Drug Resistance 
De novo emergence of drug resistance has been observed, with the presence of 
multiple unfixed drug-resistance mutations and selective sweeps in Mtb populations 
within patients [28–30]. Additionally, transmission of resistant strains is frequently 
observed [31, 32]. Indeed, many mutations associated with antimicrobial resistance 
have been identified [33], some have been associated with no fitness cost and others 
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with additional compensatory mutations that may increase fitness and enable 
transmission [34]; this area requires further investigation. Such mutations include both 
point mutations, for example, single nucleotide polymorphisms (SNPs) such as in rpoB 
[35] and structural variants such as the dfrA-thyA double deletion linked to para-
aminosalicylic acid resistance [36]. Genes involved in resistance to some drugs are well 
known; for example, mutations for rifampicin (in rpoB and rpoC) and isoniazid (in katG) 
are well characterised [33]. However, the mechanisms for ethambutol (embB), 
pyrazinimde (pncA) and second line drugs are not fully known. As whole genome 
sequencing (WGS) is applied to Mtb more routinely [37] , association approaches using 
genomic variation have the potential to provide new insights into these resistance 
mechanisms. Compensatory mutations such as those in rpoA and rpoC, associated with 
the rpoB rifampicin resistance mutations, have been associated with transmission of 
drug resistant strains [38]. 
 
Whole Genome Sequencing 
WGS is increasingly being applied to Mtb, either after culturing or directly from 
sputum[39–42]. A number of tools have been developed to predict drug susceptibility 
from genome sequence [43–50]. 
Additionally, WGS has important implications for TB surveillance; it allows the 
phylogenetic reconstruction of relationships between strains and thus the inference of 
transmission events [51–54]. Such inference of transmission events can be used to 
inform public health strategy. Furthermore, WGS can enable the monitoring of drug 
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resistance evolution at a genomic level, for example determining the relative 
importance of within patient evolution versus transmission of drug resistance [28–32]. 
 
Genome-Wide Discovery Methods 
Genome Wide Association 
The genome-wide association study (GWAS) approach has been applied as a method to 
discover genomic variants involved in drug resistance phenotypes. 
This approach seeks to identify genomic variants associated with phenotypes of 
interest, classically through case-control designs, in which the genomic data of a group 
with the phenotype of interest is compared to that of a group without the phenotype 
of interest, and statistical association is assessed. Such methods are firmly established 
in the field of human genetics research.  
However, there are important differences between humans and bacterial 
pathogens in relation to GWAS methodology that must be considered. Haploid 
organisms like bacteria often form highly structured populations resulting from 
transmission and clonal reproduction. They may even group into distinct lineages, 
which may have important biological differences encoded in their genome. Thus, there 
is a need to deal with population structure, such that relatedness is accounted for, 
minimising spurious associations as a result of common genetic background, whilst 
maximising sensitivity to detect biologically relevant effects. Furthermore, for many 
bacterial species, there are added complications, such as lateral gene transfer, which 
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can lead to variable gene content between isolates; there may be differences in the 
presence or absence of entire genes [55].  
With the development of linear mixed model approaches that seek to account 
for relatedness [56] and increasing availability of bacterial whole genome sequences, 
there is new potential in the application of GWAS to understand evolutionary dynamics 
in bacterial pathogens [57].  
It is interesting to note that human GWAS typically rely on typed SNPs, and 
exploit patterns of known linkage disequilibrium, the patterns by which variants in 
close proximity are commonly co-inherited, within human populations, to link SNPs to 
potential causal genomic variants. However, WGS data negates the need for 
characterised linkage disequilibrium patterns and allows the possibility of detecting 
causal variants directly. 
The GWAS approach, widely used in human genetics, is increasingly being 
applied to pathogen research and shows great promise [58]. It allows the identification 
of variants across the genome, associated with specific phenotypes, and has been used 
in humans, for example, to identify variants in the class II human leukocyte antigens 
(HLA) region associated with susceptibility to TB infection [59]. In order to prevent 
spurious associations, pathogen GWAS face the need to deal with the much higher 
levels of population structure seen in bacteria compared to humans, whilst maximising 
sensitivity [56, 60]. This is especially prescient for Mtb due to its clonality. 
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GWAS has been demonstrated as a useful methodology for investigating drug 




PhyC is a methodology that seeks to identify genomic signatures of selection resulting 
from convergent evolution. This occurs when a mutation independently becomes fixed 
multiple times. To detect such events, ancestral reconstruction is performed for each 
variant, using parsimony to infer at which node in the phylogenetic tree the mutation 
event likely occurred. The variant frequency in branches with the phenotype in 
question can then be compared to the variant frequency in branches without the 
phenotype and tested for statistical difference [65]. 
These methods have yet to be universally applied across pathogen species. As a 
clonal bacterial pathogen with no evidence of lateral gene transfer, Mtb, the causal 
agent of TB, may prove to be a useful organism on which to develop such methods. 
This is especially prescient in relation to drug resistance phenotypes, as the use of anti-
microbial therapy represents a strong selective force on Mtb. 
Convergence-based methods have been used to identify resistance mutations in 
Mtb [65, 66]. Such methods seek to identify convergent evolution in phenotypically 
resistant strains. This occurs when mutations in the same gene or nucleotide position 
repeatedly and independently become fixed, thus signalling positive selection for a 
particular phenotype. 
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Previous applications of convergence-based methods in Mtb have resulted in 
the identification of a number of new targets of independent selection in relation to 
drug resistance, including a mutation in ponA1 [65] and prpR [66]. It was shown 
through functional genetic analyses that strains carrying the ponA1 mutation showed a 
survival advantage during in vitro growth in the presence of rifampicin [65]; whilst 
common variants in prpR were found to confer multidrug tolerance [66].  
Furthermore, both association and convergent evolution analyses have been 
successfully combined together, resulting in the finding that loss of function mutations 
in ald confer resistance to D-cycloserine in Mtb [67]. Although there have been notable 
difficulties in disentangling individual drug resistance-conferring variants from drug 
resistance phenotypes that are not directly related, due to co-occurring drug resistance 
phenotypes as a result of combined drug therapy, and there is a need for further 
methods development [61, 67]. 
 
Application of Machine Learning 
Broadly, there has been interest in the application of machine learning methods to 
predict drug resistance in Mtb. A number of methods have been employed, 
demonstrating their potential utility in predicting resistance phenotypes from Mtb 
genome sequence, including support vector machines (SVM), k-nearest neighbour 
clustering, random forests and neural networks [68–76]. Such applications include 
approaches that did not require the need for mapping next generation sequencing 
(NGS) reads to a reference sequence [68]. Unlike GWAS and phyC, which detect 
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additive effects, such approaches might offer capability to detect epistasis [68]. 
However, explainability of some machine learning models can be limited, and due to 
high computational costs, such analyses are often restricted to specific loci already 
known to be involved in resistance. 
 Learning classifier systems (LCS) may offer an interesting approach to 
disentangling epistatic interactions in relation to drug resistance in Mtb. LCS broadly 
work through the creation of populations of rules; collectively these rules form the 
model. Each rule predicts phenotype based on the state of one or more attributes. 
During prediction, rules across the whole population ‘vote’ for a specific phenotype. 
Rule populations are formed through supervised learning; a genetic algorithm is 
employed in which rules can reproduce, recombine and mutate as a function of their  
prediction accuracy, with preference for more general rules to prevent overfitting [77]. 
Thus, LCS can be considered to employ an evolutionary approach to learning. 
 In this way, LCS may cope with epistasis- where multiple attributes contribute 
to a phenotype, as well as heterogeneity within the genomics of a specific phenotype- 
where multiple different genomic mechanisms can underpin the phenotype. Further to 
this, inspection of rules within the rule population may provide insight into the 
biological mechanisms involved in a given phenotype. 
 
Data 
The data used throughout this work comprises of WGS data coupled with drug 
resistance phenotype data aggregated from multiple studies (see Chapters 2-5). Clinical 
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isolates from individual patients underwent WGS and drug susceptibility testing; 
isolates were cultured and susceptibility was tested using phenotypic testing protocols 
recognized by WHO [63,78]. This resulted in a binary phenotype for resistance versus 
susceptibility. Each isolate was not necessarily tested for susceptibility to each drug; 
where isolates were found to be susceptible to first-line treatments, they often did not 
undergo additional drug susceptibility testing for second-line treatments.  
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Project Overview 
This work is structured in four parts, as explained below. 
 
Title Published 
Genome-wide analysis of Mycobacterium tuberculosis polymorphisms 
reveals lineage- specific associations with drug resistance 
2019 
Genome-wide analyses identify novel associations with Extensively 
Drug Resistant tuberculosis 
Under 
Review 
Genome-wide machine learning classifier applied to Mycobacterium 
tuberculosis as a novel approach to unravel genomic complexity 
associated with drug resistance 
In prep. 
Genome-wide Learning Classifier System applied to Extensively Drug 
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b Number of variants per sample;; variants called in comparison to the 
H37Rv reference, with monomorphic variants removed for each dataset. 
a Total  numbers of variants by lineage; variants called in comparison to 
the H37Rv reference, with monomorphic variants removed for each 
dataset. 
c Non-reference variant frequency summary; variants called in comparison to 
the H37rv reference; variants called in comparison to the H37rv reference, with 
monomorphic variants removed for each dataset. 
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Non-reference variant frequency histogram 
Histograms showing log10(frequency+1) of non-reference alleles compared 


























































































Population diversity within investigated strains. 
a Principal component 1 (PC1) by principal component 2 (PC2) for lineage 2, The first 10 
principal components account for 71.9% of the variation in lineage 2; b Distance plot for 
lineage 2 showing pairwise number of variant differences between samples; c Principal 
component 1 (PC1) by principal component 2 (PC2) for lineage 4, the first 10 principal 
components account for 88.9% of the variation in lineage 4.  d Distance plot for lineage 2 
showing pairwise number of variant differences between samples.  
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Scree plots showing the proportion of variation accounted for by the first ten principal 
components, calculated for the pairwise distances within a lineage 4 and b lineage 2. 
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Additional File 5 
 
Drug-resistance phenotype frequency table by lineage; ‘Total’ shows the 
number and percentage by lineage of known drug-resistance phenotypes. 
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Cross-Resistance Table upper triangle shows proportion of samples 
with a known phenotype for both vertical and horizontal phenotype, 
that test positive for vertical phenotype. Diagonal (in bold) shows 
number of samples with a known phenotype for each phenotype. 
Lower triangle shows number of samples with a known phenotype 
for both horizontal and vertical phenotype. 
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Variant Position Table detailing variants at all positions with at least one non-synonymous 
variant found to be significantly associated with a phenotype in any of the variant-based 
analyses. 
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Additional File 8 
   
 
 
Locus Comparison Table showing which analyses and in which lineage each loci was 
identified. A ‘x’ indicates a locus which was not identified by the method of analysis in 
question. Loci without a known association with the phenotype are highlighted in bold. 
There were 9 loci identified by Coll et al. (2018) using the wider non-lineage specific 
dataset that were not identified here13.  
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Study frequency table, showing numbers and percentage of strains from each 
study by lineage. 
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Additional File 10 
 
 
Sublineage frequency table; numbers and percentage by  lineage 
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ABSTRACT 
Rationale: The transmission of extensively drug resistant Mycobacterium tuberculosis 
(XDR-TB) is threatening the control of tuberculosis disease. Whole genome sequencing 
of XDR-TB and non-XDR-TB strains can provide much needed insights into the loci and 
specific mutations underlying drug resistance and transmission. 
Objectives: To examine the genomic basis of XDR-TB. 
Methods: We characterised 613,821 single nucleotide polymorphisms (SNPs) from 
whole genome sequencing data for a global dataset of 18,255 M. tuberculosis isolates 
representing the four main M. tuberculosis lineages. The SNPs were applied in genome-
wide association study (GWAS) and convergent evolution analysis approaches to 
identify genetic markers of XDR-TB. 
Measurements and Main Results: Through GWAS we identify 20 loci in novel 
associations within highly drug-resistant M. tuberculosis strains, including Rv2000 and 
espA-ephA, that may enhance transmissibility. Cluster-based GWAS and a lack of 
overlap with associations identified through convergent-evolution-based analyses 
confirmed that many of the novel associations have been driven by transmission in 
outbreaks of highly-resistant M. tuberculosis.  
Conclusions: Our XDR-TB genomic analysis revealed direct resistance-conferring 
mutations, as well as markers of high transmissibility.  
ABSTRACT WORD COUNT: 175 
KEYWORDS: Mycobacterium tuberculosis, antimicrobial resistance, transmission 
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INTRODUCTION 
Tuberculosis disease (TB), caused by Mycobacterium tuberculosis (Mtb), is an 
important global public health issue, with 10 million new cases, and 1.6 million deaths 
in 2017 (1). The evolution of antimicrobial resistance in Mtb poses a serious threat to 
global TB control efforts. Resistant Mtb can be categorised as multi-drug resistant 
(MDR-TB), defined as resistance to two first–line drugs, rifampicin and isoniazid, or 
extensively-drug resistant (XDR-TB), defined as MDR-TB Mtb that is additionally 
resistant to fluoroquinolones and at least one second-line injectable. About 8.5% of 
MDR-TB cases were XDR-TB in 2017. At least 123 countries have had at least one XDR-
TB case. Transmission of XDR-TB Mtb has been observed in the community, including in 
TB endemic South Africa (2). There is evidence of a genomic basis of transmissibility 
(3,4) (Sobkowiak et al., under review), though such complex phenotypes have been less 
studied than drug resistance outcomes. Genome wide association studies (GWAS) and 
convergent evolution-based approaches are proving useful in characterising the 
genetic basis of drug resistance in Mtb (5–7), with evidence of differing resistance 
genomics between the seven lineages into which members of the Mtb complex are 
categorised (8,9). They have also identified compensatory mutations, defined as 
mutations that restore fitness when costly resistance conferring variants are present in 
the genome, which have been suggested as drivers of transmission (10,11). The 
importance of these compensatory mutations in the Mtb genome in contributing to 
XDR-TB remains to be established (12,13). 
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An improved understanding of XDR-TB evolution, and in particular transmission, is 
critical for TB disease control. With the increasing availability of whole genome 
sequence (WGS) data for highly resistant XDR-TB isolates, it has become possible to 
take a more detailed look at the related Mtb population genomics. Here we perform 
GWAS analysis on a global dataset of >18,000 lineage 1, 2 ,3 and 4 Mtb isolates to 
identify genomic variants associated with XDR-TB.  
 
METHODS 
Genomic Data and processing 
Mtb WGS raw data was available from across 18,255 isolates (see Supplementary 
Table E1 for ENA Project accession numbers), including those described in recent 
studies (14,15). Variants were called from the raw WGS data in relation to the H37rv 
reference genome using in-house pipelines, as described in (5). In brief, sequencing 
reads were trimmed using trimmomatic (16) to remove low quality sequences, and 
then mapped against the H37Rv reference genome (AL123456) using BWA (17) 
(v0.7.17). SNPs were called using SAMtools/BCFtools (v1.8) (18) in regions where at 
least 10 reads were present. SNPs were converted into a FASTA format alignment, 
which was used by ExaML software (19) to reconstruct the phylogeny for each lineage 
and combined. Drug resistance profiles and lineages were predicted in-silico using 
TBProfiler (v2.0) software (15). Lineages 1, 2, 3, and 4 were used in downstream 
analyses and isolates assigned to multiple lineages were thought to be mixed infections 
and were removed. 
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Phenotypic Data 
Resistance phenotypes were generated through laboratory-based drug susceptibility 
testing, as described in (5). Resistance phenotypes associated with the WGS data were 
collated (see Supplementary Table E2), providing a binary drug resistance phenotype 
for 15 potential drugs; amikacin, capreomycin, ciprofloxacin, cycloserine, ethambutol, 
ethionamide, isoniazid, kanamycin, moxifloxacin, ofloxacin, para aminosalicylic acid 
(PAS), pyrazinamide, rifabutin, rifampicin and streptomycin. Phenotypic data was not 
complete across all drugs, as resistance to first line treatments leads to second-line 
assessment (see Supplementary Table E2). Rifampicin and isoniazid drug susceptibility 
testing data was the most complete (>99%), and ciprofloxacin, PAS and cycloserine the 
least complete (<3%). Five composite “resistance” phenotypes were inferred from the 
phenotypic data: (i) aminoglycosides (amikacin, kanamycin or streptomycin), (ii) 
fluoroquinolones (ofloxacin, moxifloxacin or ciprofloxacin), (iii) MDR-TB (isoniazid and 
rifampicin, but not XDR-TB), (iv) XDR-TB (MDR-TB + resistance to fluoroquinolones or 
second line injectables (amikacin, kanamycin or capreomycin)) and (v) pan susceptible 
(susceptible to rifampicin and isoniazid and with no other known resistance). Low 
frequency phenotypes in each lineage were removed from downstream analyses as 
such; for each lineage, any total phenotype frequency of <100 or resistance frequency 
of <25 isolates (Supplementary Table E3). 
Association Analyses 
GWAS analyses were conducted using a statistical mixed model implemented in  
GEMMA software (20) for lineages 1, 2, 3 and 4 separately and combined. Models 
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contained individual SNPs (“variant-based”) or aggregated mutations in gene and 
intergenic regions (“locus-based”). They also incorporated a kinship matrix (“random 
effect”) to account for bacterial genetic relatedness, as described in (9). A conservative 
p-value cut-off of 1x10-21 (1E-21) was applied, as described in (9). Convergent-based 
phyC analyses were conducted on each SNP across each lineage separately and 
combined (6). For both GWAS and phyC analyses, the phenotypes of XDR-TB and MDR-
TB were compared to the pan-susceptible phenotype. XDR-TB was additionally 
compared to the MDR-TB phenotype. For variant GWAS a minor allele frequency cut-
off of > 0.001 (0.1%) was applied. Additionally, GWAS was conducted on isolates 
belonging to XDR-TB transmission clusters (determined by pairwise SNP distance <10) 
compared to all other (XDR-TB) isolates. PE/PPE genes were removed from analyses 
due to their repetitive nature and consequent difficulties in mapping these regions 
(21). 
Functional Classification 
Functional classification was conducted for loci identified to be in novel association 
with resistance phenotypes, using the STRING database (22). For intergenic loci; the 
functions of both flanking genes were included. For each novel loci, genes linked by 
neighbourhood, co-occurrence, co-expression, experiments, databases, text mining or 






Lineages, drug resistance and transmission 
In total 18,255 Mtb isolates were included in analyses. The majority were in lineage 4 
(n=8,892; 47.3%), followed by lineage 2 (n=4,761; 25.3%), lineage 3 (n=2,860; 15.2%) 
and lineage 1 (n=2,270; 12.1%). There was a total of 10,924 (58.2%) pan susceptible, 
3,804 (20.3%) MDR-TB and 351 (1.9%) XDR-TB (Supplementary Table E3). There were 6 
(1.7%), 163 (46.4%), 28 (8.0%), and 154 (44.0%) XDR-TB isolates in lineages 1, 2, 3 and 
4, respectively. The majority of pan susceptible isolates were in lineage 4 (n=5,838, 
53.4%) (see Supplementary Table E3). Lineage 1 had the greatest diversity, as 
measured by the number of SNPs difference (mean=896.3, median=983.0), whereas 
lineage 2 had the lowest (mean=322.0, median=244.9) (see Supplementary Table E4, 
Supplementary Figure E1).  
By looking at the XDR-TB isolates that were <10 SNPs different from each other, we 
determined potential transmission networks (lineage (no. samples in networks): 1 (0), 
2 (67), 3 (7), and 4 (95)) (see Supplementary Figure E2, Supplementary Figure E3,  
Supplementary Figure E4, Supplementary Figure E5, Supplementary Figure E6, 
Supplementary Figure E7). The most numerous sub-lineage with transmission events 
being 4.3.3 (Euro-American (LAM), n=54), followed by 2.2.2 (East-Asian (Beijing), n=45) 
(see Supplementary Table E4). Of the XDR-TB isolates that were <10 SNPs different to 
at least one other isolate, 107 were from South Africa, 22 from Belarus, 21 from 
Portugal, 7 from Argentina, 7 from Pakistan, 3 from Brazil and 2 from China (see 
Supplementary Table E4).  
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GWAS analyses reveal known and novel loci associated with MDR-TB and XDR-TB 
A GWAS association approach revealed eleven loci known to be involved with drug 
resistance phenotypes, including MDR-TB and XDR-TB. These loci were embB, embC-
embA, gyrA, gyrB,  inhA, katG, oxyR’-ahpC, pncA, rpoB, Rv1482c-fabG1 and ubiA (see 
Supplementary Tables E5 and E6). An analysis of the same phenotypes using phyC 
detected eleven loci: eis-Rv2417c, embB, embC-embA, gyrA, inhA, katG, rpoB, rpsL, 
rrs, and Rv1482c-fabG1 (see Supplementary Table E7, overlaps with GWAS indicated in 
bold). 
Across all GWAS analyses there were 31 novel associations relating to 20 loci (see 
Tables 1 and 2). There were 21 novel associations with XDR-TB compared to pan 
susceptibility, involving 15 loci (aroG, cydB-cydA, echA2-mazF1, pks6, PPE13-Rv0879c, 
recF, Rv0197, Rv0530A-Rv0531, Rv1373, Rv1616, Rv1924c-fadD31, Rv3235, Rv3238c-
Rv3239c, Rv3554-Rv3555c, Rv3755c-proZ); seven novel associations with XDR-TB 
compared to MDR-TB, involving three loci (espA-ephA, Rv0571c-Rv0572c, Rv2000);  and 
three novel associations with fluoroquinolones, involving three loci (folD-relJ, Rv0530A-
Rv0531, ligC-Rv3732). No novel associations were identified with individual drug 
resistance phenotypes in either the locus- or SNP-based GWAS, except ciprofloxacin for 
lineage-combined, which this was excluded due to lineage-specific phenotype 
frequency threshold (see Tables 1 and 2). 
Distinguishing Lineage-combined from lineage specific effects 
For lineage-combined locus-based GWAS analyses, one novel association was identified 
between Rv3755c-proZ and XDR-TB compared to pan susceptible (p-value= 4.15E-59) 
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(see Table 1). For SNP-based GWAS analyses, seven novel associations were identified 
for seven loci. Three loci ( (Rv1616, pks6, Rv1373 and Rv0197) in association with XDR-
TB compared to pan susceptible (p-values< 2.78E-23). A further four loci (Rv2000, 
Rv0571c-Rv0572c and espA-ephA) in association with XDR-TB compared to MDR-TB (p-
values< 2.11E-22) (see Table 2). Additionally, we identified one significant novel 
association with ciprofloxacin involving Rv2128 (p-value= 4.4E-22). The only novel 
association identified solely by lineage-combined GWAS analyses was pks6 (see Table 
2). PhyC based analysis identified 20 non-synonymous SNPs in novel association with 
resistance phenotypes in 14 loci; Rv0336, Rv1765c, Rv3611, Rv0797, Rv1150, Rv2015c, 
Rv1588c, pks12, Rv0515, Rv0094c, Rv2186c, Rv2512c, Rv1042c, Rv3115, Rv3193c (P-
values< 10E-5, see Supplementary Table E8). 
Lineage-specific analysis 
No novel associations were found for any of the lineage 1 specific GWAS analyses (see 
Tables 1 and 2; Supplementary table E5). Seven associations with known resistance 
loci were identified (locus-based: rpoB , Rv1482c- fabG1, katG, pncA and embB; 
variant-based: katG, embB, rpoB, rrs, Rv1482c-fabG1 and inhA). PhyC analyses found 
two novel associations (Rv1204c and Rv2186c), both in association with ethambutol 
(both Fisher-test p-value= 2.57E-06) (see Supplementary Table E8). 
For lineage 2, specific locus-based GWAS analyses, novel associations were identified 
for three loci (Rv1924c-fadD31, aroG and Rv3235) in association with XDR-TB 
compared to pan susceptible (p-values< 7.76E-25, respectively) (see Table 1). For SNP-
based GWAS analyses, Rv1373 was identified in association with XDR-TB compared to 
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pan susceptible (p-value= 2.62E-31) (Table 2). Application of phyC did not detect 
lineage 2 specific associations (see Supplementary Table E8). 
For lineage 3 specific locus-based GWAS analyses, five novel associations were 
identified for four loci; Rv0530A-Rv0531 and Rv3554-Rv3555c in association with XDR-
TB compared to pan susceptible (p-values< 1.11E-22) and folD-relJ, Rv0530A-Rv0531 
and ligC-Rv3732 in association with fluoroquinolones (p-values < 8.96E-23) (see Table 
1). For SNP-based GWAS analyses, one novel association was identified; PPE13-
Rv0879c identified in association with XDR-TB compared to pan susceptible (p-value= 
1.04E-24) (see Table 2). There were no associations identified by lineage 3 specific 
phyC (see Supplementary Table E8). 
For lineage 4 specific locus-based GWAS analyses, four novel associations were 
identified for four loci; Rv3755c-proZ, Rv3238c-Rv3239c and cydB-cydA, in association 
with XDR-TB compared to pan susceptible (p-values < 2.24E-24) and Rv0571c-Rv0572c 
in association with XDR-TB compared to MDR-TB (p-value= 5.93E-31) (see Table 1). For 
SNP-based GWAS analyses, seven novel associations were identified across seven loci. 
In particular, four loci (recF, Rv1616, echA2-mazF1 and Rv0197) were revealed in 
association with XDR-TB compared to pan susceptible (p-values < 6.02E-22). Whilst, a 
further three loci (Rv2000, Rv0571c-Rv0572c and espA-ephA) were in association with 
XDR-TB compared to MDR-TB (p-values< 2.23E-29) (see Table 2). The Rv0571c-Rv0572c 
was identified by locus-based and SNP-based GWAS analyses in association analysis 
with XDR-TB compared to MDR-TB. The application of PhyC revealed no novel 
 79 
associations, but found known associations of rpoB with MDR-TB and rifampicin 
resistance (fisher-test p-value< 1.72E-07) (see Supplementary Table E8). 
Functional Characterisation 
Analysis of the functional annotation of the locus-based GWAS hits revealed that LigC, 
of ligC-Rv3732, is a DNA ligase involved in DNA repair, and Rv3239c, of Rv3238c-
Rv3239c, is similar to antibiotic resistance, and efflux proteins (see Table 1). 
Annotation of the locus-based GWAS hits with associated proteins from STRING 
revealed, folD of folD-relJ is associated with thyX and thyA, Rv0571c of Rv0571c-
Rv0572c is associated with hspX, and Rv3554-Rv3555c is associated with fas and 
echA20 (see Supplementary Table E9). Similarly, analysis of the SNP-based GWAS hits 
revealed that recF is involved in replication and repair and espA-ephA is associated with 
ESX-1 secretion. Annotation of the SNP-based GWAS hits with associated proteins from 
STRING revealed several pathways: (i) recF is associated with gyrA and gyrB, (ii) Rv2000 
is associated with ubiA  and ephA  (see Supplementary Figure E6), (iii) Rv0571c-
Rv0572c Is associated with hspX, and (iv) pks6 is associated with fas (see 
Supplementary Table E9). 
Functional annotation of the novel associations identified by phyC revealed that, 
amongst other functions, four loci are transposases or putative transposases (Rv2512c, 
Rv1042c, Rv3115, Rv0797) and three loci are members of the 13E11 repeat family 




Transmission Cluster GWAS 
The locus-based transmission cluster GWAS comparing XDR-TB transmission clusters to 
all isolates revealed an association with Rv0571c-Rv0572c (p-value= 1.45E-34) (See 
Supplementary Table E10). The similar SNP-based analyses revealed associations in 
two known drug resistant loci: rpoB (p-value=3.08E-284) and ubiA (p-value=1.9E-129) 
(see Supplementary Table E10). rpoB was previously identified by locus-based GWAS, 
SNP-based GWAS and phyC (see Supplementary Tables E5, E6, and E7). ubiA was 
previously identified by SNP-based GWAS and phyC, but not locus-based GWAS (see 
Supplementary Tables E5, E6, E7). Additionally, the SNP-based transmission cluster 
GWAS, which compared XDR-TB transmission clusters to all isolates, revealed 
associations with three loci identified by the non-cluster-based methods. In particular, 
these were Rv2000 (p-value= 2.09E-310), Rv0571c-Rv0572c (p-value= 1.33E-201) and 
espA-ephA (p-value= 4.46E-173) (see Supplementary Table E10). The SNP-based 
transmission cluster GWAS comparing Mtb isolates in XDR-TB transmission clusters to 
all other isolates, revealed associations with nine loci identified by the non-cluster-
based methods. In particular, these were Rv1061 (p-value= 8.57E-95), mce2B (p-value= 
2.32E-81), iniA (p-value= 1.88E-30), Rv2425c (p-value= 1.88E-30), Rv1144-mmpL13a (p-
value= 1.07E-27), Rv3471c (p-value= 1.07E-27), atsD (p-value= 1.31E-24), secD (p-
value= 8.76E-24), and Rv2499c (p-value= 2.29E-23) (see Supplementary Table E10). A 
locus-based GWAS of XDR-TB transmission clusters compared to non-clustering XDR-TB 
also identified Rv0571c-Rv0572c (p-value=2.15E-21). SNP-based GWAS of cluster XDR 
compared to non-cluster XDR also identified rpoB (p-value= 6.78E-27), Rv2000 (p-
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value= 6.78E-27), espA-ephA (p-value= 4.87E-23) and Rv0571c-Rv0572c (p-value= 9.5E-
23) (see Supplementary Table E10). 
 
Rv2000, which had the  most significant association from the SNP-based transmission 
cluster GWAS comparing XDR-TB transmission clusters to all isolates (see 
Supplementary Table E10), was found in 48 clustering isolates and seven isolates that 
did not belong to an XDR transmission cluster, all of which belonged to sub-lineage 
4.3.3. Of the non-XDR-cluster isolates with the Rv2000 mutation, one was XDR-TB, two 
were MDR-TB and none were pan-susceptible (see Figure 1). All Rv2000 mutant 
isolates were from South Africa. A STRING pathway analysis linked Rv2000 to ephA, 
Rv2001, fabG3, ubiA, yidC, ctpB, fhaA, atsD, Rv0493c and mmpL13a (see 
Supplementary Figure E7). 
 
DISCUSSION  
The application of GWAS to this global Mtb dataset has revealed a number of lineage 
specific associations between genomic variants and XDR-TB. This is one of the largest 
MDR-/XDR-TB genomic studies, and one reason for the numerous novel associations 
with XDR-TB could be increased statistical power. However, many of these variants 
could have become frequent due to transmission in XDR-TB outbreak settings. Lack of 
overlap between novel GWAS findings and novel phyC findings further supports this 
conclusion; suggesting higher relative importance of transmission versus convergent 
evolution in the development of these GWAS identified variants. Indeed, if there is a 
genomic contribution to transmissibility, as has been suggested (3), transmissibility and 
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drug resistance might be presumed to coevolve; more virulent, less latent strains, 
would likely experience more drug therapy and increased selection for resistance. A 
genetic component that increases the rate of transmission of MDR-TB or XDR-TB 
strains could account for these observations, meaning that these strains could be 
exposed to more drug therapy and thus more selection pressure to develop both drug 
resistance and transmission success. Occurrence of outbreaks are likely multifactorial, 
caused by factors including behaviour, environment and genomics. Thus, it is unclear 
the relative importance of selection versus genetic drift in increasing frequencies of the 
associated variants identified amongst XDR-TB outbreaks; nevertheless, our work 
shows these variants are compatible with XDR-TB transmission and present in clinically 
important outbreak strains and thus warrant further study. 
Some of the variants identified may play a role in directly conferring resistance whilst 
others may play a role in compensating phenotypes with reduced fitness as a result of 
costly resistance mutations. Interestingly, a number of novel associated variants 
identified have been linked to known resistance conferring mutations, such as folD-relJ 
(linked to thyX; thyA), recF (linked to gyrA and gyrB) and Rv2000 (linked to ubiA). The 
Rv0197 locus has previously been implicated in transmissibility (3), here we find it to be 
in association with  XDR-TB for lineage 4 and lineages-combined GWAS analyses. 
The Rv2000 locus may be of particular interest, considering its highly significant 
association with XDR-TB transmission. Rv2000 has an unknown function (22), but 
interestingly has been linked to ephA including through potential gene fusion, 
coexpression of putative homologs in other species and interaction of putative 
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homologs in other species (22). The intergenic region espA-ephA was detected by our 
analyses. EphA is an epoxide hydrolase with suggested involvement in detoxification of 
extraneous host- cell epoxides (22). There is potential for these loci to be implicated in 
the transmissible XDR-TB phenotype and thus they merit further exploration. 
Additionally, Rv2000 has been linked in the literature to ubiA, which is itself linked to 
ethambutol resistance, and mmpl13a, a probable conserved transmembrane transport 
protein; the intergenic region Rv1144-mmpL13a  was identified by cluster variant 
GWAS analysis (23,24).  
Overall, most novel associations identified by phyC were identified through lineage-
combined rather than lineage specific analyses. This is concordant with the idea that, in 
contrast to GWAS, phyC gains power from more diverse datasets with a greater 
magnitude of convergent evolution and thus may be particularly suited to identifying 
independent mutation events leading to drug resistance . 
In conclusion, through lineage specific GWAS, we have identified genetic associations 
with XDR-TB that are cluster specific and not directly associated with drug resistance. 
These loci are consistent with expansion of XDR-TB clones through transmission chains 
and may be compensatory or transmission associated. Further work into the biological 
impact of these variants would provide a deeper understanding into the potential 
biological mechanisms of their involvement with XDR-TB. The identification of 
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Figure 1- Maximum likelihood phylogenetic tree based on SNPs for lineage 4 showing 





Table 1 showing all novel associations identified by locus-based GWAS across all 
lineages and resistance phenotypes.  
Locus Comparison Lineage P-value Function  




Conserved protein  
Rv0530A-
Rv0531 









Conserved protein  
folD-relJ Fluoroquinolones 3 3.96E-
44 













integral membrane protein 

























Hypothetical unknown ala-, 
arg-, pro-rich protein 




Probable cydB, cytochrome 
D ubiquinol oxidase 
subunit II, integral 
membrane protein 
ligC-Rv3732 Fluoroquinolones 3 8.96E-
23 
DNA ligase C 




Possible electron transfer 
protein 
XDR-TB = extensively drug resistant TB; MDR-TB = multi-drug resistant TB 
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Table 2 showing all novel associations identified by SNP-based GWAS across all 
lineages and resistance phenotypes, where the SNPs have a minor allele frequency of 




Comparison Lineage P-value Odds 
ratio 
Function 




1.37,  DNA replication 
and repair 
protein 
Rv1616 1815877 XDR-TB vs. Pan 
Susc., XDR-TB 










Rv2000 2246032 XDR-TB vs 
MDR-TB, XDR-
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Rv1373 1546703 XDR-TB vs. Pan 
Susc., XDR-TB 











4056430 XDR-TB vs 
MDR-TB, XDR-



















PPE13- 978350 XDR-TB vs. Pan 3 1.04E- 2.57 Uncharacterized 
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Rv0197 232574 XDR-TB vs. Pan 
Susc., XDR-TB 














Figure 1- Maximum likelihood phylogenetic tree based on SNPs for lineage 4 showing 
distribution of Rv2000 variant and transmission chain 
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Supplementary Table E1- ENA project codes of isolates used in the study 
 
 
Project Drug-resistant MDR-TB Susceptible XDR-TB Total 
cryptic_nejm_2018(25) 754 2391 5124 0 8269 
PRJEB10385 210 303 106 95 780 
PRJEB11653 77 35 14 0 126 
PRJEB14199 34 14 0 77 125 
PRJEB15857 8 20 20 0 48 
PRJEB2138 4 13 8 11 38 
PRJEB2221 19 6 333 0 358 
PRJEB2358 30 2 290 0 322 
PRJEB2424 2 40 3 0 51 
PRJEB2777 0 0 93 0 93 
PRJEB2794 79 7 1198 0 1284 
PRJEB5162 14 2 176 0 192 
PRJEB6276 0 0 3 0 3 
PRJEB6945 0 0 55 0 55 
PRJEB7056 177 42 890 0 1186 
PRJEB7281 16 41 38 2 110 
PRJEB7669 3 234 0 11 248 
PRJEB7727 12 5 13 0 59 
PRJEB9680 71 249 717 2 1039 
PRJNA183624 43 140 85 67 335 
PRJNA187550 0 94 44 23 161 
PRJNA200335 6 47 25 58 136 
PRJNA235852 35 20 157 0 212 
PRJNA282721 283 91 1485 5 1864 
PRJNA355614 0 0 0 0 1633 
PRJNA376471 0 8 12 0 20 
PRJNA49659 0 0 35 0 36 
Total 1877 3804 10924 351 18783 




Supplementary Table E2- Number of tested isolates for each drug 
Drug No. Tested 
% 
Tested Susceptible Resistant Resistant % 
Rifampicin 16296 86.8% 11879 4417 27.1% 
Isoniazid 16211 86.3% 11053 5158 31.8% 
Ethambutol 14655 78.0% 12108 2547 17.4% 
Pyrazinamide 11808 62.9% 10016 1792 15.2% 
Streptomycin 5161 27.5% 3833 1328 25.7% 
Ofloxacin 1982 10.6% 1477 505 25.5% 
Kanamycin 1830 9.7% 1194 636 34.8% 
Capreomycin 1721 9.2% 1333 388 22.5% 
Amikacin 1427 7.6% 1093 334 23.4% 
Ethionamide 938 5.0% 609 329 35.1% 
Moxifloxacin 870 4.6% 767 103 11.8% 
PAS 406 2.2% 363 43 10.6% 
Cycloserine 390 2.1% 286 104 26.7% 
Ciprofloxacin 394 2.1% 331 63 16.0% 
Fluoroquinolones - - 10924 574 - 
MDR-TB - - 10924 3707 - 
XDR-TB - - 10924 342 - 




Supplementary Table E3- Distribution of drug resistance types by lineage 
Lineage Drug-resistant MDR-TB Susceptible XDR-TB Total 
1 207 147 1477 6 2270 (12.1%) 
2 481 1591 1423 163 4761 (25.3%) 
3 214 424 2186 28 2860 (15.2%) 
4 975 1642 5838 154 8892 (47.3%) 
Total 1877 (10.0%) 3804 (20.3%) 10924 (58.2%) 351 (1.9%) 18783 (100.0%)  
MDR-TB = multi-drug-resistant TB; XDR-TB = extensively-drug-resistant TB 
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Supplementary Table E4- XDR-TB isolates of pairwise distance <10 SNPs cluster 
summary by lineage 
  
Sub-lineage Country Frequency Total 
2.2.1  Belarus 14 22 
China 2 
South Africa 6 
2.2.2 South 45 45 
3 Pakistan 2 2 
3.1 Pakistan 2 2 
3.1.2 Pakistan 3 3 
4.1.1.3 South Africa 4 4 
4.1.2.1  Argentina 7 9 
Belarus 2 
4.3.2.1 South Africa 2 2 
4.3.3  Belarus 6 54 
South Africa 48 
4.3.4.1 Brazil 3 3 
4.3.4.2 Portugal 21 21 
4.4.1.1 South Africa 2 2 
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Supplementary table E5- Locus-based GWAS hits involving known resistance loci  
Locus P-value Drug Lineage 
pncA 0 Pyrazinamide All 
rpoB 9.80E-278 Rifampicin All 
katG 2.31E-273 Isoniazid All 
pncA 4.13E-255 Pyrazinamide 4 
katG 4.76E-219 MDR-TB vs. PAN All 
rpoB 4.19E-215 MDR-TB vs. PAN All 
rpoB 2.97E-178 Rifampicin 4 
katG 2.02E-156 Isoniazid 4 
rpoB 1.20E-150 Rifampicin 1 
rpoB 2.74E-142 Rifampicin 3 
rpoB 4.18E-130 FQ All 
oxyR'-ahpC 1.92E-129 Isoniazid All 
Rv3795 3.50E-126 Ethambutol All 
Rv3795 4.58E-119 Ethambutol 4 
katG 2.92E-116 MDR-TB vs. PAN 4 
rpoB 4.26E-116 MDR-TB vs. PAN 4 
oxyR'-ahpC 2.13E-105 MDR-TB vs. PAN All 
rpsL 1.74E-103 Streptomycin 2 
rpoB 4.80E-95 MDR-TB vs. PAN 3 
rpoB 1.22E-93 Rifampicin 2 
rpsL 8.28E-93 Streptomycin All 
gyrA 4.89E-92 Ofloxacin 4 
katG 2.61E-90 Isoniazid 2 
rpoB 5.23E-89 MDR-TB vs. PAN 1 
rpoB 4.20E-85 FQ 2 
Rv3919c 2.23E-84 AG 4 
Rv3795 1.16E-79 Ethambutol 3 
pncA 3.08E-77 Pyrazinamide 3 
katG 3.29E-76 MDR-TB vs. PAN 2 
rpoB 9.97E-74 AG All 
Rv3795 1.22E-73 Pyrazinamide 4 
Rv3919c 1.66E-73 AG All 
rpoB 1.40E-67 FQ 4 
katG 6.10E-65 Isoniazid 3 
Rv1482c-fabG1  2.78E-61 Isoniazid 1 
rpoB 8.80E-61 XDR-TB vs. PAN All 
pncA 1.45E-59 XDR-TB vs. PAN All 
rpoB 3.46E-58 MDR-TB vs. PAN 2 
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katG 1.29E-57 AG All 
Rv3795 4.19E-57 Pyrazinamide All 
rpsL 4.87E-57 AG 2 
rpoB 8.19E-55 Pyrazinamide 4 
Rv3795 2.19E-50 Ethambutol 2 
Rv1482c-fabG1  4.76E-49 Isoniazid 3 
katG 6.07E-49 MDR-TB vs. PAN 3 
pncA 7.42E-48 Ethambutol All 
rpoB 1.64E-47 AG 3 
oxyR'-ahpC 9.07E-47 Isoniazid 4 
Rv3919c 1.27E-46 Streptomycin All 
katG 1.56E-46 AG 4 
katG 2.39E-46 FQ All 
pncA 3.48E-46 FQ All 
katG 3.88E-45 Isoniazid 1 
eis-Rv2417c 1.99E-44 FQ 3 
oxyR'-ahpC 3.75E-44 Isoniazid 2 
pncA 7.35E-43 XDR-TB vs. PAN 2 
rpoB 1.05E-42 AG 4 
katG 2.66E-42 AG 3 
rpsL 5.86E-42 AG All 
embB 1.29E-40 Ethambutol 1 
oxyR'-ahpC 1.63E-40 MDR-TB vs. PAN 4 
Rv1482c-fabG1  2.86E-40 MDR-TB vs. PAN 1 
embC-embA 4.23E-40 Ethambutol 4 
gyrA 6.09E-40 Ciprofloxacin All 
rpoB 9.64E-40 FQ 3 
oxyR'-ahpC 1.73E-39 AG All 
pncA 2.18E-39 FQ 2 
pncA 2.69E-39 Pyrazinamide 2 
Rv3795 3.88E-39 Pyrazinamide 3 
rpoB 5.01E-39 Ethambutol All 
Rv1482c-fabG1  7.57E-39 Isoniazid All 
pncA 3.31E-38 Ethambutol 4 
embC-embA 6.73E-38 Ethambutol All 
rpoB 1.48E-37 XDR-TB vs. PAN 2 
rpoB 1.97E-37 Ethambutol 1 
rpoB 9.87E-37 Isoniazid All 
oxyR'-ahpC 1.22E-35 MDR-TB vs. PAN 2 
katG 1.60E-35 Rifampicin All 
rpoB 8.11E-35 Pyrazinamide All 
Rv1482c- fabG1  9.44E-35 Isoniazid 4 
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rpoB 1.84E-34 XDR-TB vs. PAN 4 
Rv3919c 8.20E-34 Streptomycin 4 
pncA 1.07E-32 XDR-TB vs. PAN 4 
rpoB 2.08E-32 Ethambutol 4 
rpoB 3.00E-30 Ethambutol 3 
Rv3806c 1.02E-29 Ethambutol All 
rpoB 1.50E-29 AG 1 
katG 2.51E-29 FQ 4 
rpsL 6.53E-29 Streptomycin 4 
gyrA 4.28E-28 Ciprofloxacin 3 
katG 4.45E-28 AG 1 
oxyR'-ahpC 5.77E-28 FQ All 
rpoB 1.42E-26 AG 2 
embC-embA 9.67E-26 XDR-TB vs. PAN All 
rpoB 9.79E-26 XDR-TB vs. PAN 3 
katG 1.00E-25 MDR-TB vs. PAN 1 
Rv3795 1.01E-25 FQ All 
pncA 1.13E-25 Pyrazinamide 1 
Rv3806c 6.80E-25 Ethambutol 4 
katG 8.82E-24 FQ 2 
katG 9.40E-23 AG 2 
gyrA 9.94E-23 Moxifloxacin All 
gyrA 5.92E-22 XDR-TB vs. MDR-TB 4 
AG = Aminoglycosides; MDR-TB = multi-drug resistant TB; FQ = Fluoroquinolones; PAN 
= Pan susceptible; XDR-TB = extensively drug resistant TB  
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Supplementary Table E6- SNP-based GWAS hits involving known resistance loci  
Position P-value Locus Drug Lineage 
2155168 8.01E-203 katG AG 3 
761110 9.06E-164 rpoB FQ 3 
761155 7.14E-159 rpoB XDR-TB vs. PAN 3 
761155 8.35E-157 rpoB XDR-TB vs. PAN All 
1473246 5.13E-126 rrs Amikacin All 
761155 5.45E-125 rpoB XDR-TB vs. PAN 4 
761155 2.12E-120 rpoB FQ 3 
2155168 6.06E-109 katG Isoniazid All 
761155 4.05E-101 rpoB FQ All 
2155168 1.04E-99 katG AG 4 
2155168 1.60E-96 katG Isoniazid 4 
761110 1.40E-94 rpoB XDR-TB vs. PAN 4 
1473246 1.05E-93 rrs Amikacin 4 
2155168 3.80E-91 katG FQ 4 
2155168 1.73E-90 katG Isoniazid 1 
761110 2.66E-86 rpoB XDR-TB vs. PAN All 
4247429 2.44E-85 embB Ethambutol 1 
2155168 1.06E-84 katG AG 1 
1473246 4.09E-84 rrs Capreomycin All 
2155168 1.38E-82 katG AG All 
2155168 1.29E-81 katG MDR-TB vs. PAN 1 
761155 1.68E-79 rpoB Rifampicin 1 
2155168 4.32E-79 katG FQ All 
761155 2.28E-78 rpoB Rifampicin All 
761155 2.73E-78 rpoB FQ 4 
760314 2.08E-73 rpoB Rifampicin All 
760314 7.78E-72 rpoB MDR-TB vs. PAN All 
1472362 2.18E-71 rrs AG 1 
761155 1.31E-70 rpoB Rifampicin 4 
1473246 2.42E-70 rrs XDR-TB vs. PAN 3 
2155168 1.40E-68 katG XDR-TB vs. PAN 3 
1473246 9.54E-68 rrs Capreomycin 4 
761155 2.16E-66 rpoB AG 3 
1473246 2.85E-66 rrs Kanamycin All 
1673425 1.01E-64 Rv1482c-fabG1 Isoniazid 1 
2155168 3.17E-64 katG Isoniazid 3 
761139 1.62E-60 rpoB Rifampicin All 
761110 2.30E-60 rpoB FQ All 
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761110 1.05E-58 rpoB Rifampicin All 
761155 3.06E-55 rpoB AG 1 
781687 5.21E-55 rpsL Streptomycin All 
761139 3.37E-54 rpoB Rifampicin 4 
2155168 9.94E-54 katG XDR-TB vs. PAN All 
2155168 2.09E-53 katG XDR-TB vs. PAN 4 
2155168 3.19E-53 katG Isoniazid 2 
1673425 5.05E-53 Rv1482c-fabG1 Isoniazid All 
1473246 1.16E-52 rrs Kanamycin 4 
761110 1.55E-51 rpoB Rifampicin 4 
2155168 3.86E-51 katG FQ 3 
781687 1.25E-50 rpsL Streptomycin 2 
2155168 5.75E-50 katG MDR-TB vs. PAN All 
1673425 9.56E-50 Rv1482c-fabG1 Isoniazid 4 
1673425 2.11E-49 Rv1482c-fabG1 MDR-TB vs. PAN 1 
761155 4.81E-48 rpoB MDR-TB vs. PAN 4 
761155 7.37E-48 rpoB Rifampicin 3 
2155168 2.52E-47 katG MDR-TB vs. PAN 3 
2155168 5.66E-46 katG MDR-TB vs. PAN 4 
761155 3.01E-45 rpoB MDR-TB vs. PAN All 
7582 1.86E-43 gyrA Ciprofloxacin All 
7582 2.39E-42 gyrA Ofloxacin 4 
4247429 5.23E-42 embB Ethambutol All 
7582 6.54E-42 gyrA Ofloxacin All 
760314 1.87E-40 rpoB Rifampicin 4 
761139 5.33E-40 rpoB Rifampicin 1 
1472362 8.46E-40 rrs Streptomycin 1 
761110 1.80E-37 rpoB MDR-TB vs. PAN All 
1673425 4.65E-37 Rv1482c-fabG1 Isoniazid 3 
4247429 5.65E-37 embB AG 1 
761155 1.11E-36 rpoB XDR-TB vs. PAN 2 
1473246 6.28E-36 rrs Pyrazinamide 3 
761140 1.07E-34 rpoB Rifampicin All 
763123 1.18E-34 rpoB XDR-TB vs. MDR-TB 4 
761155 1.25E-34 rpoB FQ 2 
4247429 5.17E-34 embB Ethambutol 3 
4247429 7.48E-34 embB Ethambutol 4 
761110 1.56E-33 rpoB MDR-TB vs. PAN 4 
4247431 3.75E-33 embB Ethambutol 3 
761155 4.01E-33 rpoB MDR-TB vs. PAN 1 
760314 2.44E-32 rpoB MDR-TB vs. PAN 4 
761139 1.04E-31 rpoB MDR-TB vs. PAN All 
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781822 2.41E-31 rpsL Streptomycin All 
761139 3.60E-31 rpoB MDR-TB vs. PAN 4 
7570 9.79E-31 gyrA Ofloxacin All 
1473246 1.52E-30 rrs AG 3 
1473246 1.52E-30 rrs FQ 3 
1472362 2.07E-30 rrs Streptomycin All 
761110 2.93E-30 rpoB FQ 4 
4269271 4.08E-30 ubiA XDR-TB vs. MDR-TB 4 
761109 1.12E-29 rpoB XDR-TB vs. PAN All 
761155 2.44E-29 rpoB Rifampicin 2 
761277 4.94E-29 rpoB FQ All 
1473246 4.99E-29 rrs XDR-TB vs. PAN All 
7582 8.16E-29 gyrA XDR-TB vs. PAN 3 
761140 3.12E-28 rpoB Rifampicin 3 
1473246 4.73E-28 rrs XDR-TB vs. MDR-TB 3 
761155 6.12E-28 rpoB MDR-TB vs. PAN 3 
2155168 9.08E-28 katG MDR-TB vs. PAN 2 
4249583 1.62E-27 embB XDR-TB vs. PAN 3 
1472362 1.72E-27 rrs AG All 
2289213 1.91E-27 pncA Pyrazinamide 4 
761139 5.96E-27 rpoB Rifampicin 2 
2289213 7.81E-27 pncA Pyrazinamide All 
761155 2.32E-26 rpoB AG 4 
763123 2.32E-26 rpoB XDR-TB vs. MDR-TB All 
761155 3.24E-26 rpoB AG All 
761110 3.63E-26 rpoB Rifampicin 3 
6750 5.62E-26 gyrB XDR-TB vs. MDR-TB 4 
1674481 7.65E-26 inhA XDR-TB vs. PAN 4 
7570 8.49E-26 gyrA Ofloxacin 4 
7582 8.61E-26 gyrA Moxifloxacin All 
761109 1.06E-25 rpoB FQ 3 
761155 1.41E-25 rpoB Ethambutol 1 
2155168 1.55E-25 katG XDR-TB vs. PAN 2 
1674481 2.70E-25 inhA XDR-TB vs. PAN All 
781687 3.09E-25 rpsL AG 2 
1472359 7.24E-25 rrs AG 4 
761140 1.02E-24 rpoB MDR-TB vs. PAN All 
1472359 2.82E-24 rrs AG 1 
4247429 4.37E-24 embB XDR-TB vs. PAN All 
781822 5.29E-24 rpsL Streptomycin 2 
4247431 7.44E-24 embB Ethambutol All 
761109 9.52E-24 rpoB XDR-TB vs. PAN 3 
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7582 1.21E-23 gyrA Moxifloxacin 4 
761161 1.81E-23 rpoB Rifampicin All 
7581 7.49E-23 gyrA Ofloxacin All 
1674782 1.75E-22 inhA AG 1 
781687 3.28E-22 rpsL Streptomycin 4 
761161 8.10E-22 rpoB MDR-TB vs. PAN All 
761161 1.00E-21 rpoB MDR-TB vs. PAN 4 
AG = Aminoglycosides; MDR-TB =multi-drug resistant TB; FQ = Fluoroquinolones; PAN = 
Pan susceptible; XDR-TB = extensively drug resistant TB  
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Supplementary Table E7- Phyc hits involving known resistance loci (P<10-5) 
 
Lineage Phenotype Position Fisher Test 
P-value 
Locus 
1 Isoniazid 2155168 5.63E-62 katG 
1 Isoniazid 1673425 1.50E-40 Rv1482c-fabG1 
1 Rifampicin 761155 2.97E-33 rpoB 
All Rifampicin 761155 4.85E-30 rpoB 
1 MDR-TB vs. PAN 761155 6.46E-30 rpoB 
All MDR-TB vs. PAN 761155 7.61E-30 rpoB 
1 MDR-TB vs. PAN 2155168 1.62E-29 katG 
1 MDR-TB vs. PAN 1673425 1.05E-23 Rv1482c-fabG1 
All MDR-TB vs. PAN 781687 2.08E-22 rpsL 
All Rifampicin 4247431 2.19E-21 embB 
All Rifampicin 781687 1.93E-20 rpsL 
All Rifampicin 4247429 2.06E-19 embB 
1 Isoniazid 761155 2.41E-19 rpoB 
1 Ethambutol 4247429 8.14E-19 embB 
All MDR-TB vs. PAN 4247431 1.67E-17 embB 
All MDR-TB vs. PAN 1673425 3.11E-17 Rv1482c-fabG1 
1 MDR-TB vs. PAN 4247429 3.44E-17 embB 
All MDR-TB vs. PAN 4247429 3.94E-17 embB 
All MDR-TB vs. PAN 761139 1.17E-16 rpoB 
All Ethambutol 4247429 3.90E-16 embB 
1 Rifampicin 761139 5.69E-16 rpoB 
All Rifampicin 761139 8.64E-16 rpoB 
All MDR-TB vs. PAN 2155168 1.34E-15 katG 
All Rifampicin 7582 3.45E-15 gyrA 
1 Rifampicin 2155168 4.59E-15 katG 
1 AG 2155168 6.68E-15 katG 
All Ethambutol 761155 7.57E-15 rpoB 
1 Ethambutol 761155 7.58E-15 rpoB 
1 Rifampicin 4247429 7.69E-15 embB 
1 MDR-TB vs. PAN 761139 7.70E-15 rpoB 
All MDR-TB vs. PAN 7582 1.21E-14 gyrA 
1 Rifampicin 1673425 1.95E-13 Rv1482c-fabG1 
All AG 781687 2.91E-13 rpsL 
1 Isoniazid 4247429 3.25E-12 embB 
All Rifampicin 2155168 5.12E-12 katG 
All Ethambutol 781687 7.64E-12 rpsL 
All AG 761155 8.00E-12 rpoB 
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All Rifampicin 1673425 1.48E-11 Rv1482c-fabG1 
All Pyrazinamide 781687 2.05E-11 rpsL 
All Rifampicin 1473246 3.27E-11 rrs 
All Streptomycin 4247429 1.78E-10 embB 
1 MDR-TB vs. PAN 761140 3.89E-10 rpoB 
1 Isoniazid 761139 7.78E-10 rpoB 
1 AG 1472362 1.11E-09 rrs 
All Streptomycin 781687 1.13E-09 rpsL 
All MDR-TB vs. PAN 1473246 1.13E-09 rrs 
All Ethambutol 4247431 1.17E-09 embB 
1 AG 761155 1.22E-09 rpoB 
All AG 2155168 1.98E-09 katG 
All Rifampicin 7570 2.20E-09 gyrA 
All Ethambutol 2155168 2.82E-09 katG 
1 Ethambutol 2155168 2.90E-09 katG 
All Pyrazinamide 761155 3.31E-09 rpoB 
1 Isoniazid 761140 3.40E-09 rpoB 
1 Isoniazid 1472362 3.40E-09 rrs 
1 Rifampicin 761140 3.51E-09 rpoB 
All FQ 1473246 4.51E-09 rrs 
All AG 4247429 6.23E-09 embB 
All Ethambutol 761139 9.24E-09 rpoB 
1 Streptomycin 1472362 2.28E-08 rrs 
All AG 7570 2.53E-08 gyrA 
All Rifampicin 4247730 3.00E-08 embB 
All AG 1473246 4.05E-08 rrs 
All Streptomycin 7582 5.64E-08 gyrA 
All Streptomycin 761155 6.03E-08 rpoB 
All FQ 7570 7.40E-08 gyrA 
All Streptomycin 2155168 8.62E-08 katG 
1 MDR-TB vs. PAN 1472362 8.75E-08 rrs 
4 MDR-TB vs. PAN 761155 9.17E-08 rpoB 
1 Ethambutol 4243217 1.03E-07 embC-embA 
1 Ethambutol 761139 1.10E-07 rpoB 
1 FQ 2155168 1.14E-07 katG 
All Rifampicin 761140 1.18E-07 rpoB 
All MDR-TB vs. PAN 7570 1.32E-07 gyrA 
All Rifampicin 2715342 1.63E-07 eis-Rv2417c 
1 FQ 1473246 1.67E-07 rrs 
4 Rifampicin 761155 1.72E-07 rpoB 
All Amikacin 1473246 2.45E-07 rrs 
All Ethambutol 1473246 2.57E-07 rrs 
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All Amikacin 781687 2.77E-07 rpsL 
All Pyrazinamide 1473246 3.04E-07 rrs 
All AG 761139 3.16E-07 rpoB 
All Pyrazinamide 4247429 4.31E-07 embB 
All Ofloxacin 7570 4.91E-07 gyrA 
1 XDR-TB vs. PAN 761155 5.05E-07 rpoB 
All MDR-TB vs. PAN 2715342 5.20E-07 eis-Rv2417c 
All Rifampicin 1472359 5.49E-07 rrs 
1 MDR-TB vs. PAN 4247431 5.78E-07 embB 
All Ethambutol 7570 5.82E-07 gyrA 
1 FQ 4247429 6.65E-07 embB 
4 Rifampicin 4247431 7.37E-07 embB 
All Streptomycin 761139 7.93E-07 rpoB 
All Streptomycin 7570 8.00E-07 gyrA 
All XDR-TB vs. PAN 1473246 9.43E-07 rrs 
All MDR-TB vs. PAN 4247730 1.08E-06 embB 
All ethambutol 7582 1.25E-06 gyrA 
1 MDR-TB vs. PAN 4247730 1.31E-06 embB 
1 MDR-TB vs. PAN 4243217 1.31E-06 embC-embA 
1 MDR-TB vs. PAN 1472359 1.31E-06 rrs 
1 Rifampicin 4247730 1.37E-06 embB 
1 Rifampicin 4243217 1.37E-06 embC-embA 
All Ethambutol 761140 1.42E-06 rpoB 
1 FQ 761155 1.66E-06 rpoB 
All Rifampicin 761161 1.72E-06 rpoB 
All MDR-TB vs. PAN 761140 2.00E-06 rpoB 
All MDR-TB vs. PAN 1472359 2.00E-06 rrs 
All AG 7582 2.27E-06 gyrA 
1 Rifampicin 4247431 2.28E-06 embB 
1 Ethambutol 4269293 2.57E-06 ubiA 
1 Ethambutol 1673425 3.23E-06 Rv1482c-fabG1 
All FQ 2155168 3.92E-06 katG 
All Rifampicin 1673432 3.98E-06 Rv1482c-fabG1 
All MDR-TB vs. PAN 1673432 4.23E-06 Rv1482c-fabG1 
1 AG 1673425 4.33E-06 Rv1482c-fabG1 
All AG 1673425 4.57E-06 Rv1482c-fabG1 
All MDR-TB vs. PAN 1674263 4.65E-06 inhA 
1 Ethambutol 761140 5.22E-06 rpoB 
1 MDR-TB vs. PAN 4248003 7.44E-06 embB 
1 Pyrazinamide 761155 7.44E-06 rpoB 
1 Rifampicin 4248003 7.73E-06 embB 
1 Rifampicin 1472359 7.73E-06 rrs 
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1 Streptomycin 781822 8.03E-06 rpsL 
1 Isoniazid 4247431 8.26E-06 embB 




Supplementary Table E8- Novel non-synonymous PhyC hits (P<10-5); for all 
phenotypes and lineages; specific and combined 
Gene SNP 
Position 
Phenotype Min. Fisher 
test P 
Lineage Function 
Rv0336 401318 Rifampicin, MDR-TB 








1.50E-51 All Conserved 
13E12 repeat 
family protein 








4.25E-19 All Uncharacterized 
protein 
Rv1765c 1998063 MDR-TB vs. PAN 2.91E-16 All Uncharacterized 
protein 
Rv3611 4053161 Rifampicin, MDR-TB 
vs. PAN, AG, FQ 




Rv0797 891220 MDR-TB vs. PAN, 
Rifampicin, 
Ethambutol, AG 
9.33E-13 All Putative 
transposase for 
IS1547 
Rv1150 1278278 Rifampicin, MDR-TB 








Rv2015c 2262620 Amikacin, 
Rifampicin, 
Capreomycin, MDR-
TB vs. PAN, 
Ethambutol 
4.00E-10 All Uncharacterized 
protein 
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Rv0797 890549 Rifampicin, 
MDRvPAN 
1.10E-09 All Putative 
transposase for 
IS1547 
Rv3611 4053050 Rifampicin, MDR-TB 
vs. PAN, 
Streptomycin 




Rv1588c 1789446 Ciprofloxacin 1.68E-08 All Uncharacterized 
protein  
pks12 2295685 Rifampicin, MDR-TB 
vs. PAN, 
Ethambutol 
2.54E-07  All Polyketide 
synthase  
Rv0515 607677 MDR-TB vs. PAN, 
AG, Streptomycin 
1.08E-06 All Conserved 
13E12 repeat 
family protein 
Rv0094c 103756 AG 2.20E-06 All Member of 
13E12 repeat 
family 
Rv2186c 2447616 Ethambutol 2.57E-06 1 Uncharacterized 
protein 
Rv2512c 2829656 Pyrazinamide 3.69E-06 All Transposase for 
insertion 
sequence 
element IS1081  
Rv1042c 1165114 MDR-TB vs. PAN, 
Rifampicin 
5.19E-06 All Probable is like-
2 transposase 
Rv3115 3482432 Ethionamide 6.16E-06 All Probable 
transposase 




AG = Aminoglycosides; MDR-TB =multi-drug resistant TB; FQ = Fluoroquinolones; PAN = 
Pan susceptible; XDR-TB = extensively drug resistant TB  
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Supplementary Table E9- novel hits with their STRING associations 
Locus Rv Analysis STRING Associations 
recF Rv0003 variant dnaA dnaN gyrA* gyrB* recA recO recR recX rnpA 
Rv0004 
Rv0197 Rv0197 variant lppM narX Rv0196 Rv0218 Rv0236.1 Rv2172c 
Rv2813 Rv3403c Rv3549c Rv3777 
iniA Rv0342 cluster 
variant 
iniB iniC Rv0049 Rv0110 Rv0312 Rv0339c Rv0340 
Rv2264c Rv3863 whiB6 




















Rv1734c Rv3127 Rv0571c Rv3126c rip3 Rv3129 









Rv0048c Rv0157A Rv0381c Rv0531 Rv0680c 









aftA aftC Rv0466 Rv0955 Rv1476 Rv1610 Rv3035 
Rv3635 Rv3668c Rv3802c 
mce2B Rv0590 cluster 
variant 
lprL mce2A mce2C mce2D mce2F Rv0590A yrbE2A 
yrbE2B yrbE4A yrbE4B 
atsD Rv0663 cluster 
variant 
atsA atsB rnz Rv0296c Rv0712 Rv2000 Rv3077 
Rv3406 Rv3762c Rv3796 
Rv1061 Rv1061 cluster 
variant 
fadD14 Rv0426c Rv1059 Rv1060 Rv1062 
Rv1144- Rv1144 cluster bioF1 echA10 hycD mcr mmpL13a purH Rv2635 
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efpA mmpL1 mmpL13a mmr Rv0590A Rv0849 
Rv1144 Rv1877 Rv2000 Rv3836 
Rv1373 Rv1373 variant PE_PGRS2 PE_PGRS23 PE_PGRS48 pks18 PPE39 
PPE40 PPE53 PPE64 Rv1371 Rv1676 
Rv1616 Rv1616 variant crcB1 pykA Rv1517 Rv1610 Rv1615Rv1619 Rv1861 
Rv2203 Rv2433c tesB1 
cydB-
cydA 








Rv1924c locus fadD31 
Rv1924c-
fadD31 
Rv1925 locus fadD22 fadD9 mbtE mbtF nrp pks13 Rv0068 
Rv0149 Rv0149 Rv1924c tesA 
Rv2000 Rv2000 variant; 
cluster 
variant 
atsD ctpB ephA fabG3 fhaA mmpL13a Rv0493c 
Rv2001 ubiA* yidC 
aroG Rv2178c locus aroB aroD aroE aroK pheA pheA Rv0948c Rv1885c 
Rv2179c Rv2180c trpA 
Rv2425c Rv2425c cluster 
variant 
kgd mobA oxyR proA Rv0370c Rv2424c Rv2426c 
Rv2456c 
Rv2499c Rv2499c cluster 
variant 
accA1 accD1 citE fadD35 fadE19 Rv0575c Rv2506 
scoA scoB yrbE3B 
secD Rv2587c cluster 
variant 
ffh ftsY Rv2585c secA1 secE1 secF secG secY yajC 
yidC 
Rv3235 Rv3235 locus fadD16 Rv0428c Rv1045 Rv1125 Rv1682 Rv2712c 
Rv3231c Rv3231c Rv3289c Rv3415c tgs3 
Rv3238c-
Rv3239c 




Rv3239c locus gltB lipJ ribG Rv0104 Rv1364c Rv1937 Rv2209 
Rv2434c Rv3238c secA1 
folD-relJ Rv3356c locus fmt gcvT glyA1 glyA2 guaA purH purN purU thyA* 
thyX* 
folD-relJ Rv3357 locus ccdA higB3 relB relE relF relG relK Rv3359 vapB2 
vapC2 
Rv3471c Rv3471c cluster 
variant 
gmdA ilvB2 mhpE mrsA Rv0521 Rv1508A Rv2305 
Rv3468c Rv3472 udgA 
Rv3554-
Rv3555c 




Rv3555c locus fadA6 Rv0083 Rv0336 Rv0393 Rv0515 Rv0756c 
Rv1765c Rv2100 Rv2642 Rv3776 










echA1 ephG espA folE lpqG Rv1056 Rv2000 
Rv3612c Rv3613c Rv3618 
ligC-
Rv3732 








Rv3755c locus mmpR5 proV proW proX proZ Rv0513 Rv2739c 
Rv3479 Rv3489 Rv3760 
Rv3755c-
proZ 
Rv3756c locus cobL hsaF lpqZ proV proW proX Rv0191 Rv1667c 
Rv3008 Rv3755c 
* Loci known to be involved in resistance
 116 
 
Supplementary Table E10- SNP-based cluster GWAS comparing the transmission 
clusters groups versus others 
Position P-value Locus Links to 
candidates* 
2246032 2.09e-310 Rv2000 ubiA 
763123 3.08E-284 rpoB 
 
664929 1.33E-201 Rv0571c-Rv0572c*** 
 
4056430 4.46E-173 espA-ephA Rv2000 
4269271 1.90E-129 ubiA Rv2000  
1184080 8.57E-95 Rv1061 
 
688228 2.32E-81 mce2B 
 
410962 1.88E-30 iniA 
 
2722670 1.88E-30 Rv2425c 
 
1272321 1.07E-27 Rv1144-mmpL13a 
 
3889150 1.07E-27 Rv3471c 
 
763123** 6.78E-27 rpoB 
 
2246032** 6.78E-27 Rv2000 ubiA 
756757 1.31E-24 atsD Rv2000 
2915226 8.76E-24 secD 
 
2813575 2.29E-23 Rv2499c 
 
4056430** 4.87E-23 espA-ephA Rv2000 
664929** 9.50E-23 Rv0571c-Rv0572c 
 
* in STRING database; ** comparison group is the non-transmitted XDR-TB; *** also 













Supplementary Figure E2 (cont.)
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Supplementary Figure E3- lineage 1 maximum likelihood tree with novel associations 
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Supplementary Figure E4- lineage 2 maximum likelihood tree with novel associations 
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Supplementary Figure E5- lineage 3 maximum likelihood tree with novel associations 
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The identification of genomic variants in whole genome sequencing data associated 
with Mycobacterium tuberculosis (Mtb) drug-resistance rely on genome-wide 
association study (GWAS) or convergent evolution approaches. However, these 
methods are potentially limited in their ability to detect multiple interacting loci 
contributing towards drug resistance. We investigate the use of a (machine) learning 
classifier system (LCS) to gain insights into within genome interactions, with the aim of 
developing an approach capable of disentangling complex drug resistance genomics, 
for use in predicting phenotypes and discovering novel loci involved in resistance. 
Results 
The LCS algorithm parameters and performance were benchmarked on the rifampicin 
anti-TB drug for which we know the underlying genes (e.g. rpoB) involved in resistance.  
We achieved a sensitivity of 93.7% and a specificity of 94.8% in predicting rifampicin 
resistance, and the model included rpoB and rpoC, known to be epistaticly involved in 
drug resistance. We then applied LCS to isoniazid resistance and multi-drug (rifampicin 
and isoniazid) resistance, achieving sensitivity of 86.8% and 93.5% and specificity of 
94.2% and 97.6%, respectively. Additionally, we identified candidate loci for novel 
involvement in resistance such as celA1. Our work demonstrates the potential of 
machine learning approaches to disentangle complex genomic interactions and provide 
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mechanistic inferences in relation to drug resistance in Mtb, without the requirement 
for prior knowledge. 
 132 
INTRODUCTION 
The evolution of drug-resistant Mycobacterium tuberculosis (Mtb) is threatening the 
control of tuberculosis disease, with multi-drug resistant (MDR-TB)  forms making up 
82% of the 558,000 new cases in 2017 with resistance to rifampicin – the most 
effective first-line drug [1]. Large whole-genome sequence (WGS) datasets are 
increasingly becoming available for Mtb, coupled with drug resistance phenotype data, 
enabling the possibility of precision public health and diagnostics. This advance would 
require a deeper understanding of the genomic basis of drug resistance in Mtb, in all its 
complexity.  
Drug resistance in Mtb can be due to mutations (including single nucleotide 
polymorphisms (SNPs), insertions and deletions (indels)) in genes coding for drug-
targets or -converting enzymes. However, the full repertoire of resistance variants 
across the more than sixteen anti-TB drugs is unknown, and other mechanisms that are 
compensatory or related to efflux pumps have been described [2]. Current methods 
employed to gain insight into Mtb genomics and drug resistance include genome-wide 
association studies (GWAS) using  linear mixed models [2,3] and convergent evolution 
analysis [4]. Recently, machine learning approaches such as random forest  [5], support 
vector machines [6,7] and deep learning [8,9] have been applied and show promise. 
However, such methods are often limited in their ability to detect complex genetic 
interactions, known as epistasis, especially those involving more than two loci, in a 
mechanistically explainable way and often require prior knowledge. 
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Learning classifier systems (LCS) offer an alternative approach with scope to gain 
insight into epistatic interactions that contribute towards drug resistance, in a genome-
wide fashion, without the use of prior knowledge. They work by constructing ‘rules’ 
involving combinations of variants that are predictive of a phenotype, through 
evolutionary optimization techniques. Unlike some other machine learning methods, 
LCS allows ease of interpretation of predictive loci and therefore underlying biological 
mechanisms. The availability of computationally efficient LCS implementation libraries 
allows for the approach to be applied on large datasets. Here, we apply LCS to an Mtb 
global dataset consisting of >18k isolates with whole genome sequences (>600k SNPs; 
>6000 genes/intergenic regions) and drug susceptibility testing-based phenotypes for 
first-line rifampicin and isoniazid drugs [10]. We optimize the parameters and assess 
the performance of LCS on rifampicin, which has known resistance gene (rpoB, and 
compensatory rpoC) mechanisms.  We then apply the algorithms to establish mutation 
‘rules’ for the prediction of isoniazid resistance and MDR-TB, and assess its feasibility as 
a tool for drug resistance phenotype prediction and discovery of drug resistance.  
METHODS 
Whole Genome Sequence Data and Processing 
A global dataset of whole genome sequence data for 18,255 Mtb isolates from lineages 
1, 2, 3 and 4 was collated, alongside phenotypic drug susceptibility testing data for 
rifampicin (n=16,296; 27.1% resistance), and isoniazid (n=16,211; 31.8% resistance), 
allowing MDR-TB (n=14,322; 25.9% resistant) to be determined (see Supplementary 
Table 1). 613,821 SNPs and their genotypes were called after aligning the sequence 
 134 
data to the H37rv reference. SNP data was also collapsed by its gene or intergenic 
region,  where a binary ’locus-type’ was assigned; any loci containing one or more non-
synonymous SNPs were coded as ‘1’,  any loci that did not contain one or more non-
synonymous SNPs were coded as ‘0’, producing a dataset of 6,879 loci.  
Learning Classifier System 
For all applications, data was randomly divided into a training set (80%) and test set 
(20%), and LCS was performed using ExSTraCS (version 2.0) [10] for 30,000,000 
iterations. Two key parameters were varied in order to allow optimization: (i) 
maximum rule population size (“N”; 1000 to 5000, by 1000) and (ii) accuracy threshold 
applied to the subsumption mechanism (“acc_sub”; 0.90, 0.95, 0.99), which 
determines the minimum accuracy of a classifier in order for it to potentially subsume 
another classifer (one classifier subsumes another if it has greater or equal accuracy 
and is more general) [11]. The maximum rule population size should be large enough to 
fully explore the search space and allow useful classifiers to be kept in the rule 
population, whilst it not too large so as to unnecessarily increase the run time of the 
algorithm and keep classifiers in the population that are not useful [11]. Lower  
subsumption mechanism (sub_acc) values may perform better in noisier problem 
domains [11]. All other parameters were set as default [10], including the probability of 
a model crossover (default=0.8) and  mutation (default=0.04) operation [11]. Within 
the final rule populations, the frequencies of individual loci, their co-occurring pairs 
and whole rules were quantified. Additionally, rule lengths (the number of loci in each 
rule) were inspected. Functions for each locus were taken from STRING [12] and 
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Mycobrowser [13]. Frequency refers to total number across the total rule population, 
macro frequency refers to the total number across unique rules. The final models were 
compared to the TB-Profiler mutation panel [14], and the predictive performance was 
estimated (and compared to TB-Profiler) using sensitivity and specificity metrics, 
assuming the drug susceptibility testing result as the gold standard. 
RESULTS 
Parameter Exploration and Application to Rifampicin 
The predictive performance (sensitivity, specificity) of the LCS for rifampicin resistance 
was insensitive to the population sizes considered (see Table 1, Supplementary Figure 
1). Similarly, the sub_acc parameter was tested, and the predictive performance was 
similar across the range of values but marginally higher for the default value of 0.99 
(Table 1, Supplementary Figure 2). Therefore, the parameter settings for population 
size (N=2,000) and sub_acc (0.99) [11] (see Table 1) were applied  in subsequent 
analyses.  
The final LCS analysis for rifampicin contained 971 different rules, with the majority 
containing the rpoB gene (frequency = 850) (Table 2, Figure 1), a locus known to be 
causally involved in rifampicin resistance. The median number of loci in the rules was 4 
(range: 1 to 14) (Supplementary Table 2, Figure 1). The most numerous rule in the 
population was rpoB by itself (frequency = 14), including the reference-and mutation-
types to predict rifampicin susceptibility and resistance, respectively (Supplementary 
Table 3). rpoB was most commonly found in association with katG (n=182, isoniazid) 
(Supplementary Table 4, Figure 2), directly as a result of some patients having 
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additional resistance to isoniazid, and therefore MDR-TB. rpoC was also detected 
(frequency = 159, rifampicin), and is a known rifampicin resistance related 
compensatory locus (see Figure 2, Supplementary Table 4). Six other loci known to be 
involved in resistance to other drugs were identified: pncA (freq=588; pyrazinamide), 
katG (freq.= 478, isoniazid), Rv1482c-fabG1 (freq.=461, isoniazid), embB (freq.=454, 
ethambutol), rrs (freq=314, streptomycin), and rpsL (freq.=132, streptomycin) (see 
Table 2). These were detected through co-occurring resistance mutations arising from 
TB patients receiving multiple drugs. Forty loci not previously established as being 
involved in drug resistance were identified, including Rv2395 (frequency=305), Rv2230c 
(frequency=253), pbpB (frequency=233), uspC (frequency=225), celA1 (frequency=209) 
and guaB2 (frequency=196) (see Table 2). Non-reference Rv2395, pbpB and uspC and 
reference guaB2 was found in rules predictive of rifampicin susceptibility.  Whilst, 
reference Rv2230c and celA1 was found in rules predictive of rifampicin resistance. The 
final model achieved a sensitivity in predicting rifampicin resistance of 93.7% and 
specificity of 95.8% (Table 1).  This is comparable to current methods (see Table 1) 
using databases of known resistance variants [5–9,14]. 
 
 
Application to Isoniazid and MDR-TB 
Applying the LCS to isoniazid resistance led to a final rule set consisting of 49 loci. The 
Rv1482c-fabG1 (frequency = 836) operon, known to be related to isoniazid resistance, 
was the locus with the highest frequency in the rule population (Supplementary Table 
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5, Supplementary Table 6, Supplementary Figure 3). In total, 7 loci known to be 
involved in drug resistance were identified, many of which signal cross-resistance with 
other drugs, similar to the rifampicin analysis; Rv1482c-fabG1 (frequency=836; 
isoniazid), rpoB (frequency=782; rifampicin), rpsL (frequency=667; streptomycin), embB 
(frequency=573; ethambutol), katG (frequency=467; isoniazid), gid (frequency=183; 
streptomycin) and rrs (frequency=110; strepromycin) (see Supplementary Table 5). 
Forty-two loci that have not previously been established as being involved in drug 
resistance were present in the rule population. The most frequent of which were 
desA3-Rv3230c (frequency=385), cyp135B1-Rv0569 (frequency=278), mmpS2 
(frequency=235), Rv3403c (frequency=233) and espF (frequency=218) (see 
Supplementary Table 5). Reference form desA3-Rv3230c was found in rules predictive 
of isoniazid resistance. Whilst, reference espF, cyp135B1-Rv0569, mmpS2 and Rv3403c 
in rules predictive of isoniazid susceptibility (see Supplementary Table 6). The most 
frequently co-occurring pair of loci was rpoB and Rv1482c-fabG1 (frequency= 308) (see 
Supplementary Table 7). The most numerous rule was non-reference rpoB with non-
reference embB in association with isoniazid resistance (see Supplementary Table 6). 
The median rule length was 4 loci (range: 1 to 13) (see Supplementary Table 2). The 
LCS achieved sensitivity of 86.8% and specificity of 94.2% in predicting isoniazid 
resistance (see Table 1).  
Applying LCS to the MDR-TB compared to pan-susceptibility detected fifty-two 
different loci across 683 different rules. The most frequent individual locus was rpoB 
(frequency=488) (see Supplementary Table 8, Supplementary Table 9, Supplementary 
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Figure 4). Nine loci known to be involved in drug resistance were identified; rpoB 
(frequency=488; rifampicin), embB (frequency=434; ethambutol), katG 
(frequency=420; isoniazid), pncA (frequency=315; pyrazinamide), rpsL (frequency=309; 
streptomycin), Rv1482c-fabG1 (frequency=288; isoniazid), gid (frequency=159; 
streptomycin), inhA (frequency=67, isoniazid) and rpoA (frequency=2; rifampicin) (see 
Supplementary Table 8). Forty-three loci that are not established drug resistance 
involved loci were identified. The most frequent of which were PPE5 (frequency=197), 
Rv3903c (frequency=164), Rv0075 (frequency=156), Rv2512c (frequency=153), 
Rv3249c (frequency=129) (see Supplementary Table 8). Non-reference PPE5, Rv3903c, 
Rv0075, Rv3249c and reference Rv2512c were found in rules predictive of pan-
susceptibility (see Supplementary Table 9). The most frequently co-occurring pair of 
loci was katG and embB (frequency= 308) (see Supplementary Table 10). The most 
numerous rule was non-reference rpoB in prediction of MDR-TB (see Supplementary 
Table 9). The median rule length was 3 (range 1 to 10) (see Supplementary Table 2). 
The final model achieved prediction sensitivity of 93.5% and specificity of 97.6% (see 
Table 1). 
DISCUSSION 
We have applied LCS to a dataset of lineages 1, 2, 3 and 4 Mtb in prediction of 
rifampicin resistance, isoniazid resistance and MDR, achieving sensitivity and specificity 
comparable to current methods and discovering a number of candidate loci for novel 
involvement in these phenotypes. 
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One limitation of this method is that by collapsing loci into reference or non-reference 
on the basis of containing one or more non-synonymous mutation, within loci 
complexities may be masked, potentially reducing resolution. Nevertheless, application 
of LCS to this Mtb dataset has provided prediction accuracy for rifampicin resistance 
comparable to current prediction methods [14], without the need for any prior 
knowledge of resistance genomics. The simultaneous consideration of multiple loci, 
within rules, may be partially responsible for this predictive power. It is interesting to 
note we found shorter rule lengths for MDR than the other phenotypes, yet more 
individual loci overall. Perhaps, this points towards the high predictive power of 
multiple resistance loci across the rule population without the need to be present 
together in long rules. One situation in which longer rules might reduce predictive 
power is where genomes are highly variable, in terms of the combinations of loci in 
which resistance mutations are present; in other words, high genetic heterogeneity of 
MDR due to independent evolution.  
Eleven loci known to be involved in drug resistance were identified across analyses by 
LCS, including rpoB which was the most frequent locus in the rule population in 
prediction of rifampicin resistance, and is known to be commonly responsible. 
Additionally, rpoC was identified by this analysis. It has been proposed that rpoC is in 
epistasis with rpoB, and it helps restore fitness when costly rifampicin-resistance 
conferring rpoB mutations are present [15,16]. 
Additionally, 125 loci were identified as novel candidates for involvement in resistance, 
and thus interesting subjects for further mechanistic exploration. One such locus is sigA 
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(rpoD), an RNA polymerase sigma factor [17]. It was identified in the rifampicin 
resistance analysis, always in reference form and always in prediction of rifampicin 
susceptibility. It is potentially an alternative mechanism directly conferring rifampicin 
resistance, or compensatory mutation in a similar fashion to rpoC. celA1 was identified 
as predictive of rifampicin resistance when in reference form. celA1 is a cellulase that 
has been shown to cause the breakdown of biofilms in M. smegmatis, where biofilms 
have been shown to be induced by exposure to rifampicin in M. smegmatis [18].  This 
observation might allude to a role of biofilm formation in drug resistance in Mtb.  If 
reference celA1 is more effective at biofilm breakdown than non-reference, the 
association between celA1 and rpoB might suggest that biofilms are not required to 
provide rifampicin resistance when rpoB is present. Conversely, if reference celA1 is 
less effective than non-reference, it could suggest that biofilm formation is a useful 
step in the evolution of rpoB in response to treatment with rifampicin. 
pbpB is also an interesting candidate for future work. It has been shown to form part of 
a ternary septation complex involved in septum synthesis. In M. smegmatis, it is 
upregulated in starved cells as they transition into a non-replicative state [19], and thus 
may play a role in phenotypic drug resistance. Interestingly, the isocitrate lyase aceA 
was also shown to be upregulated under starvation conditions in M. smegmatis [19], 
the MDR-TB analysis described here identified aceAb-PPE3; perhaps this intergenic 
region could play a role in the regulation of aceAb- a putative isocitrate lyase subunit B 
in Mtb [12]. Furthermore, uspC is an amino-sugar transporter that allows the 
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optimisation of scarce nutrient resources in Mtb [20], and was identified here  by LCS 
to be predictive of rifampicin resistance.   
Four loci identified by the isoniazid-resistance LCS, espF, eccA1, espR, and eccD1, were 
all linked to the ESX-1 secretion system. ESX-1 is a secretion system involved in 
virulence, thus it may be important to investigate how this might relate to drug 
resistance. A number of loci identified mention tRNA in their function; thrT-metT (both 
tRNA anticodons) and Rv2630-Rv2631- found by the MDR-TB analysis, tyrT-Rv0567 
(both tRNA anticodons), mpt53-Rv2879c and fusA1- found by the isoniazid-resistance 
analysis and rplS and leuU-parE2 (leuU is a tRNA anticodon) (see Table 5, Table 4, Table 
2). 
There is the additional possibility that variants in some loci identified here may not play 
a role in drug resistance phenotypes, but may instead be markers of population 
structure. However, as our analyses includes only non-synonymous variants, they may 
have important functional implications for resistant strains, regardless. For example, 
further work may be warranted regarding guaB2, identified in the rifampicin resistance 
analysis, and the impact such findings have on its potential as a new drug target, as has 
been suggested [21]. Similarly, esxV has been considered a potential vaccine candidate 
[22], it may be useful to assess how a potential link with rifampicin resistance would 
affect this. 
Our results differ from previous applications of machine learning methods to identify 
epistasis [6]; perhaps, in part, because our approach does not rely on prior knowledge 
and is genome-wide; we did not restrict analyses to specific loci. 
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In conclusion, LCS is a feasible approach to both resistance prediction and the 
disentangling of complex drug resistance genomics in Mtb, detecting known epistatic 
variants and providing novel candidates for further investigation, with scope to explore 
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Figure 1  
Rule plot for rifampicin: clockwise showing from top left; Frequency of locus against 
locus number; Rule index (the highest index is the most frequent rule) against rule 
length;  Rule index (the highest index is the most frequent rule) against locus number- 
red indicates resistance, blue indicates susceptibility, hollow points represent 
reference, filled points represent non-reference; Rule index against frequency (also 
referred to as ‘numerosity’). 
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Figure 2 
Co-occurrence heat map for rifampicin: Heat map showing co-occurring pairs of loci found 




Figure 3  
Co-occurrence heat map for isoniazid: Heat map showing co-occurring pairs of loci found 





Co-occurrence heat map for MDR-TB: Heat map showing co-occurring pairs of loci found 
in rules predictive of MDR-TB. 
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Supplementary Figure 1 
Accuracy Plots for different Rule Population Sizes (A) N=1000, (B) N=2000, (C) N=3000, 
(D) N=4000, (E) N=5000, (F) N=2000 and sub_acc=0.95 
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Supplementary Figure 2 
Numerosity Plots for different Rule Population Sizes (A) N=1000, (B) N=2000, (C) 




Supplementary Figure 3 
Rule plot for isoniazid: clockwise showing from top left; Frequency of locus against 
locus number; Rule index (the highest index is the most frequent rule) against rule 
length;  Rule index (the highest index is the most frequent rule) against locus number- 
red indicates resistance, blue indicates susceptibility, hollow points represent 
reference, filled points represent non-reference; Rule index against frequency (also 
referred to as ‘numerosity’). 
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Supplementary Figure 4 
Rule plot for MDR-TB: clockwise showing from top left; Frequency of locus against 
locus number; Rule index (the highest index is the most frequent rule) against rule 
length;  Rule index (the highest index is the most frequent rule) against locus number- 
red indicates resistance, blue indicates susceptibility, hollow points represent 
reference, filled points represent non-reference; Rule index against frequency (also 




Phenotype Sensitivity Specificity Number in 
Test Set 
Number of  
Resistant 


















rifampicin 93.9% 94.9% 3259 876 1000 30000000 0.99 95.9% 98.2% 
MDRvPAN 93.5% 97.6% 2864 742 2000 30000000 0.99 94.1% 98.3% 
rifampicin 93.7% 95.8% 3259 876 2000 30000000 0.99 95.9% 98.2% 
isoniazid 86.8% 94.2% 3242 1025 2000 30000000 0.99 93.7% 98.1% 
rifampicin 93.6% 92.9% 3259 876 2000 30000000 0.95 95.9% 98.2% 
rifampicin 93.4% 92.5% 3259 876 2000 30000000 0.90 95.9% 98.2% 
rifampicin 93.7% 95.8% 3259 876 4000 30000000 0.99 95.9% 98.2% 
rifampicin 91.4% 96.5% 3259 876 3000 30000000 0.99 95.9% 98.2% 








































































N 2 4 8 rpoB;Rv1482c-fabG1;gltB;celA1;rrs;pyrF;rpoC;Rv1129c-
prpD;katG;Rv3818;embB;pncA;Rv0140;rpsL;rplS;tgs1-
Rv3131 












209 98 celA1 N 2 4 8 rrs;embB;rpoB;rpoC;gltB;Rv2230c;katG;pncA;Rv1129c-
prpD;pyrF;Rv3818;rpsL;Rv1482c-
fabG1;Rv0140;rplS;tgs1-Rv3131 














159 96 rpoC Y 2 4 8 rpoB;celA1;embB;pncA;Rv2230c;Rv1129c-
prpD;Rv3818;pyrF;rrs;gltB;rpsL;katG;Rv1482c-
fabG1;rplS;Rv0140 































































N 2 4 8 rpoB;katG;embB;pncA;fadE10-Rv0874c;Rv1129c-
prpD;gltB;Rv1482c-
fabG1;pyrF;rpoC;Rv2230c;celA1;rpsL;rrs;Rv0140 












76 57 pyrF N 2 4 8 pncA;rrs;Rv1482c-
fabG1;Rv2230c;Rv3818;rpoB;celA1;rpoC;embB;gltB;kat
G;Rv1129c-prpD;rpsL;rplS;tgs1-Rv3131;Rv0140 
























































N 2 6 8 rpoB;pncA;embB;Rv2230c;rrs;Rv1129c-
prpD;katG;celA1;Rv3818;gltB;rpoC;pyrF;rpsL;rplS 





N 7 7 7 uspC;esxV;Rv1482c-fabG1;pncA;sigA;guaB2;Rv1254 
2 1 leuU-
parE2 
N 2 2 2 rpoB 
1 1 Rv069
0c 
N 5 5 5 Rv2395;PE_PGRS30;pncA;Rv3193c 
1 1 fadE1
0-






N 5 5 5 katG;otsB2;Rv1482c-fabG1;embB 
1 1 lipL N 6 6 6 Rv1482c-fabG1;Rv1215c;pbpB;Rv3142c;rrs 
1 1 Rv242
4c 




N 5 5 5 katG;celA1;Rv2230c;pyrF 
For ‘Known’, ‘Y’= Yes/Known, ‘N’=No/Unknown 
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7964 32.3% 7842 35.7% 2344 4946 
PRJEB10385 610 70.0% 611 78.7% 295 98 
PRJEB11653 125 44.0% 125 42.4% 35 14 
PRJEB14199 123 95.1% 123 74.0% 14 0 
PRJEB15857 38 39.5% 38 42.1% 15 18 
PRJEB2138 34 64.7% 34 70.6% 13 8 
PRJEB2221 355 2.0% 355 5.1% 6 331 
PRJEB2358 321 0.6% 321 8.7% 2 289 
PRJEB2424 45 88.9% 45 93.3% 40 3 
PRJEB2777 93 0.0% 93 0.0% 0 93 
PRJEB2794 1258 0.6% 1257 6.5% 7 1175 
PRJEB5162 185 1.6% 190 5.8% 2 174 
PRJEB6276 3 0.0% 3 0.0% 0 3 
PRJEB6945 46 0.0% 46 0.0% 0 46 
PRJEB7056 1087 4.8% 1086 13.3% 41 873 
PRJEB7281 95 45.3% 95 56.8% 41 38 
PRJEB7669 228 100.0% 231 100.0% 217 0 
PRJEB7727 28 25.0% 28 32.1% 5 12 
PRJEB9680 1019 24.3% 1019 28.0% 246 700 
PRJNA183624 329 66.0% 329 69.9% 138 83 
PRJNA187550 157 72.6% 157 72.6% 91 43 
PRJNA200335 124 78.2% 125 78.4% 43 23 
PRJNA235852 208 9.6% 208 21.6% 20 155 
PRJNA282721 1778 6.5% 1807 16.5% 87 1452 
PRJNA376471 13 38.5% 13 38.5% 5 8 




Supplementary Table 2 
Phenotype Min. Median Max. 
rifampicin 1 4 14 
MDRvPAN 1 3 10 
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Tuberculosis, caused by Mycobacterium tuberculosis bacteria, is a major global public 
health issue, with drug resistance making disease control more difficult.  Of major concern 
is the evolution of extensively drug resistant M. tuberculosis (XDR-TB), which is multidrug-
resistant tuberculosis to isoniazid and rifampicin plus resistance to fluoroquinolones and 
injectable second-line drugs. The analysis of M. tuberculosis (XDR-TB) whole genome 
sequencing (WGS) and drug susceptibility test data can improve the understanding of the 
complex combination of M. tuberculosis genetic mutations involved in XDR-TB, and thereby 
have important positive implications for surveillance, diagnosis and treatment. 
Results 
A machine learning classifier system was applied on a locus-based resolution to a global 
dataset (n=13,270; 308 XDR-TB), consisting of two M. tuberculosis lineages (2 and 4).  The 
analyses identified known resistance loci (9 for lineage 2, 13 for lineage 4), as well as 
potential novel ones (107 for lineage 2, 116 for lineage 4). The constructed models included 
loci to adjust for the confounding effect of M. tuberculosis strain-types, as well as avoided 
overfitting. They predicted XDR-TB with sensitivity of 93.9% and specificity of 98.6% for 
lineage 2 and sensitivity of 100% and specificity of 99.5% for lineage 4, which is similar to 
other recent machine learning applications. 
Conclusions 
The learning classifier system approach is an effective predictor of XDR Mtb, requiring no 
prior knowledge of M. tuberculosis genomics and could be used to inform outbreak control 





Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading global cause of 
mortality and morbidity, with the evolution of drug resistance threatening disease control. 
Extensively drug-resistant Mtb (XDR-TB) is defined as multidrug resistant (MDR-TB, 
resistance to two first-line treatments, isoniazid and rifampicin) plus additional resistance 
to fluoroquinolones and one second-line injectable. XDR-TB has been observed in at least 
123 countries, with around 8.5% of MDR TB cases being XDR in 2017 [1]. The transmission 
of XDR-TB has been observed [2] and the complexity of underlying genomics of XDR-TB 
strains has been described [3] (Oppong et al., submitted), with suggestions of epistatic 
interactions contributing to fitness in resistant strains [4, 5] and differences in genomics 
between Mtb lineages [6].  
 
The increased availability of whole genome sequencing (WGS) data for clinical Mtb isolates, 
raises the possibility of gaining a deeper understanding of XDR-TB outbreak dynamics to 
inform outbreak control strategies, diagnosis and treatment [7]. Current analytical 
approaches include the application of phylogenetic based characterisation of transmission 
clusters, and the use of GWAS and convergent evolution methods to identify mutations 
associated with drug resistance and transmissibility [8–10]. Such methods have detected 
individual known mutations in the context of MDR-TB, but there is a need to identify novel 
mechanisms to explain the XDR-TB phenotype, including any epistasis at play. The 
application of machine learning approaches has the potential to uncover new resistance 
loci [11–19]. Learning classifier systems (LCS) iteratively search for combinations of loci in 
populations of models using mechanisms inspired by biological evolution, such as 
reproduction, mutation, recombination, and selection. These approaches have the 
potential to explore large datasets and epistatic effects in relation to complex “resistance” 
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traits (Oppong et al, in prep). Here we apply an LCS approach to predict Mtb XDR-TB in a 




Data and Processing 
A global dataset of WGS data for 18,255 Mtb isolates from lineages 1 (12.1%), 2 (25.3%), 3 
(15.2%) and 4 (47.3%) was collated, alongside phenotypic drug susceptibility testing data 
across 16 anti-TB drugs (Oppong et al., under review, 2019). XDR-TB was assigned as 
combined resistance to isoniazid and rifampicin plus resistance to a fluoroquinolone 
(ciprofloxacin, levofloxacin, moxifloxacin) and to a second line injectable (amikacin, 
kanamycin, capreomycin). Pan-susceptibility was assigned as susceptibility to rifampicin 
and isoniazid alongside no other known resistance (see Supplementary Table 1, Oppong et 
al., submitted) (n=7,063, 53.2%). Only analyses where the number of XDR-TB isolates in the 
test set was >10 were included in downstream analyses, leaving lineages 2 (n=4,642) and 4 
(n=8,628). Overall the number of XDR-TB cases was 308 (lineage 2, n=155, 3.34%; lineage 4, 
n=153, 1.77%). 
 
Sequence data was aligned to the H37rv reference and variants were called, resulting in a 
total of 613,821 SNPs. A binary ’locus-type’ was assigned by collapsing SNP data by its gene 
or intergenic region. The loci containing one or more non-synonymous SNPs were coded as 
‘1’ and any loci that did not contain one or more non-synonymous SNPs were coded as ‘0’, 





Learning classifier systems (LCS)  
The ExSTraCS Learning Classifier System [20] was applied to each lineage (2 and 4) to 
construct populations of models that predict XDR-TB (vs. pan-susceptible). All parameters 
were default except the rule population size (n=2,000), which was recommended for 
complex and noisy problems [21]. For each analysis, the data was split into a training (80%) 
and test (20%) set (see Figure 1). The frequencies of entire rules, co-occurring pairs and 
individual loci were quantified in the final rule populations. Frequency is defined as the 
total number across the total rule population. Macro frequency is defined as the total 
number across unique rules. The number of loci in each rule (rule length) was also 
enumerated. Phenotypes, testing and training sets and misclassified isolates were plotted 
on lineage specific maximum likelihood phylogenetic trees, created using ExaML [22], as 
described in (Oppong et al., submitted). The functionality of loci identified in the LCS 
analysis were taken from STRING [23] and Mycobrowser [24].  
 
RESULTS 
The lineage 2 and lineage 4 analyses identified nine loci in common as predictive of XDR-
TB: embB (ethambutol), ethA (ethionamide), lppC, pncA (pyrazinamide), rpoB (rifampicin), 
rrs (streptomycin), Rv0458, Rv1482c-fabG1 (isoniazid) and Rv2434c. Of these lppC, rv0458 
and Rv2434c have not previously been implicated in drug resistance (see Table 2 and Table 
3). lppC is a putative lipoprotein, Rv0458 is a putative aldehyde dehydrogenase and 
Rv2434c is a putative conserved transmembrane protein [23]. Assuming the drug 
susceptibility test result as the gold standard, the LCS achieved a predictive performance of 
93.9% sensitivity and 98.6% specificity for lineage 2 and 100.0% sensitivity and 99.5% 
specificity for lineage 4 (see Table 1). Performing the final models on the test set resulted 
in a low misclassification error in both lineages (6/310 lineage 2, 6/1163 lineage 4) (see 
Table 1, Supplementary Figure 1). 
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Lineage 2 analysis 
Nine known resistance involved loci were identified by lineage 2 analysis: Rv1482c-fabG1, 
rpoB, ethA, rrs, embB, pncA, rpoC, rpoA and alr (see Table 2). 107 novel loci identified by 
lineage 2 analysis (see Table 2), where these included markers to stratify by different 
strain-types. The most frequent loci across the population of 2,000 models were: Rv0575c 
(frequency 186), Rv1823 (f126), hycE-Rv0088 (121), narJ (110), Rv3115-moeB2 (110) and 
ponA1 (105). The most frequently co-occurring pair of loci was Rv0575C and narJ 
(frequency 45) (see Supplementary Table 2). Whilst, the most frequently occurring rules 
were non-reference Rv1922 (frequency 11), fadE1 (11), and Rv2897c (11) in prediction of 
pan-susceptibility (Supplementary Table 3). Based on an analysis of gene function, a 
number of novel loci are candidates for directly conferring resistance, including Rv1877 
which shows similarity to drug efflux proteins [23] (see Table 2). 
 
Lineage 4 analysis 
Thirteen known resistance involved loci were identified by lineage 4 analysis: rpoB 
(rifampicin), embB (ethambutol), katG (isoniazid), ethA-ethR (ethionamide), rrs 
(streptomycin), pncA (pyrazinamide), Rv1482c-fabG1 (isoniazid), drrA, gyrB 
(fluorquinolones), rpsL (streptomycin), embC-embA (ethambutol), inhA (isoniazid) and ethA 
(ethionamide) (see Table 3). 116 novel loci were identified by lineage 4 analysis (see Table 
3), where the most frequent across the 2,000 models were fadD30 (226), Rv2059 (166), 
Rv0158 (125), vapB34 (125) and glnA3 (124) (see Table 3). Rv0158 and glnA3 was the most 
frequently occurring pair of loci (frequency 43) (see Supplementary Table 4). The most 
frequent rule in the rule population was non-reference fadE15-PE_PGRS29 in prediction of 
pan-susceptibility (12) (see Supplementary Table 5). A number of novel loci identified were 
potentially involved in efflux such as (i) Rv2025c, where Rv2024c-Rv2025c is a probable 
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cation efflux system; (ii) mctB involved in efflux of copper, and (iii) Rv0194 of Rv0193c-
Rv0194, which is a multidrug efflux protein [23] (see Table 3).  
 
DISCUSSION 
We have applied LCS to a global dataset of XDR and pan-susceptible Mtb isolates from 
lineages 2 and 4, achieving high accuracy of prediction and identifying known loci and novel 
candidates for involvement in these phenotypes.  
 
The high accuracy of XDR-TB prediction, as observed here for lineage 4, is especially 
interesting considering the model presented is based solely on loci, rather than single 
nucleotide polymorphisms or indels. It would appear even lower resolution locus-level data 
can provide enough information to predict XDR-TB phenotype, when multiple loci are being 
considered in tandem. The idea that many loci are of importance in predicting the XDR-TB 
phenotype is supported by the lower and more evenly distributed rule frequencies that 
make up the rule populations described here, compared to previous analyses predicting 
single resistance to rifampicin (Oppong et al., in prep). It follows that phenotype prediction 
through locus-level, as opposed to mutation-level, LCS may work better when the 
phenotype in question is highly complex, involving multiple loci, rather than a simple 
Mendelian trait.  
 
One factor contributing towards the higher prediction accuracy observed for lineage 4 
compared to lineage 2 could be the increased diversity in lineage 4 (Oppong et al., 
submitted). Perhaps the lineage 2 analyses could benefit from the inclusion of SNP and 
indel data or from greater numbers to capture more low frequency variants involved in the 
phenotype. Indeed, as it becomes more computationally feasible, applying the 
methodology presented here to mutation-level data could enable real-time monitoring of 
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clinical Mtb isolates to predict XDR-TB outbreaks before they occur, allowing more targeted 
resource allocation and thus more effective intervention to prevent further transmission. 
Furthermore, the high accuracy XDR-TB prediction, as achieved here, could be useful in 
diagnosis of clinical Mtb isolates in order to inform treatment regimen.  
 
There is potential that the LCS is picking up on variation unrelated to fitness of XDR Mtb 
and rather identifying markers related to population structure. Thus, it might be interesting 
to further test the LCS models developed here on new data. However, the use of only non-
synonymous mutations at locus level means any loci identified may well have functional 
importance and at the very least be descriptive of clinically relevant XDR strains. Moreover, 
it is interesting to note that both true and false predictions appear to be evenly distributed 
throughout the phylogenetic tree for each lineage.  
 
A number of understudied loci were identified, some in prediction of XDR-TB and some in 
prediction of pan-susceptibility, and thus warrant further biological investigation. These 
include potential mechanisms of drug resistance such as probable drug efflux pumps. 
The high number of novel candidate loci identified here is in keeping with the nature of this 
method. Unlike other machine learning methods previously applied to detect epistasis in 
drug resistant Mtb [11], LCS is able to identify associated loci across the entire genome, 
without the need for prior knowledge. 
 
CONCLUSIONS 
LCS is a potentially useful methodology for predicting the complex XDR-TB phenotype. It 
requires no prior knowledge, but seems to demonstrate high predictive accuracy, account 
for population structure, and identify plausible and biologically interesting loci as 
candidates for further study. Large-scale use of this approach could be useful in the real-
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time monitoring of Mtb genomics in outbreak settings, informing more targeted public 
health intervention,  especially with the extended application of LCS to individual mutation 
level data. Furthermore, its high predictive accuracy could be useful in diagnosing XDR-TB 
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Figure 1  
Rule plots lin2 and 4 XDR:(A) lineage 2 and (B) lineage 4. clockwise showing from top 
left; Frequency of locus against locus number; Rule index (the highest index is the 
most frequent rule) against rule length;  Rule index (the highest index is the most 
frequent rule) against locus number- red indicates resistance, blue indicates 
susceptibility, hollow points represent reference, filled points represent non-
reference; Rule index against frequency (also referred to as ‘numerosity’). 
  
 A-lineage 2 
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Figure 1 (cont.) 
B- lineage 4 
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Figure 2 
Heat maps showing co-occurring loci found in rules predictive of XDR for (A) lineage 2 and 





Figure 2 (cont.) 
B-lineage 4 
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Supplementary Figure 1 
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 Table 1 







XDRvPAN 100.0% 99.5% 1163 31 4 
XDRvPAN 93.9% 98.6% 310 33 2 
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Table 2 



























Possible oxidoreductase, similar to 



















Uncharacterized protein; Catalyzes the 
NADPH-dependent reduction of beta- 
ketoacyl-ACP substrates to beta-
hydroxyacyl-ACP products, the first 
reductive step in the elongation cycle 
of fatty acid biosynthesis 
 192 









DNA-directed RNA polymerase subunit 
beta- DNA-dependent RNA 
polymerase catalyzes the transcription 
of DNA into RNA using the four 
ribonucleoside triphosphates as 
substrates 





monooxygenase able to convert a 
wide range of ketones to the 








Baeyer-Villiger oxidation reaction. C 
126 51 Rv182
3 



















Possible formate hydrogenase HycE; 
Possible polyketide 
cyclase/dehydrase. Belongs to the 
SRPBCC ligand-binding domain 
superfamily. Predicted to be an outer 
membrane protein. 



































Probable IS1081 transposase; 
Probable moeB2,molybdopterin 
cofactor biosynthesis protein 




Probable arabinosyltransferase B; 
Arabinosyl transferase responsible for 
the polymerization of arabinose into 














Penicillin-binding protein 1A- cell wall 
formation. Synthesis of cross-linked 
peptidoglycan from the lipid 
intermediates. The enzyme has a 
penicillin-insensitive transglycosylase 
N-terminal domain (formation of 
linear glycan strands) and a penicillin-
sensitive transpeptidase C-terminal 
domain (cross-linking of the peptide 
 198 
subunits) (By similarity). Has little 
peptidoglycan hydrolytic activity, 
however it inhibits the synergistic 
peptidoglycan hydrolysis of RipA plus 
RpfB 







catalyzes the deamidation of 
nicotinamide (NAM) into nicotinate. 
Likely functions in the cyclical salvage 
pathway for production of NAD from 
nicotinamide 
96 34 ispE N 1 3 5 vapB35-mce3R;Rv0792c-
Rv0793;betP-
4-diphosphocytidyl-2-C-methyl-D-









phosphorylation of the position 2 
hydroxy group of 4-diphosphocytidyl-
2C-methyl-D-erythritol. Belongs to the 































Chorismate pyruvate-lyase; Removes 
the pyruvyl group from chorismate to 
provide 4- hydroxybenzoate (4HB). 





glycosylated p-hydroxybenzoic acid 
methyl esters (p-HBADs) and phenolic 
glycolipids (PGL) that play important 
roles in the pathogenesis of 
mycobacterial infections 











bifunctional protein- catalyzes the 
production of L-lysyl-tRNA(Lys)transfer 
and the transfer of a lysyl group from 





phosphatidylglycerol (PG), which 
produces lysylphosphatidylglycerol 
(LPG), one of the components of the 
bacterial membrane with a positive 
net charge. LPG synthesis contributes 
to the resistance to cationic 
antimicrobial peptides (CAMPs)  
66 12 Rv150
7c 






















Carbamoyl-phosphate synthase large 
chain 
































Probable conserved transmembrane 
protein 





ATP-dependent RNA helicase- DEAD-
box RNA helicase involved in various 
cellular processes at low temperature, 
including ribosome biogenesis, mRNA 








reductase subunit beta- provides the 
precursors necessary for DNA 
synthesis. Catalyzes the biosynthesis 
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of deoxyribonucleotides from the 
corresponding ribonucleotides. Two 
genes for this protein are present in 










Ribonuclease- toxic component of a 




N 1 3 4 vapC12;rpoB;Rv0792c-
Rv0793;Rv3115-

















Probable transcriptional regulatory 
protein (Probably GntR-family);  
Putative monooygenase that might be 
involved in antibiotic biosynthesis, or 
may act as reactive oxygen species 


















DNA-directed RNA polymerase subunit 
beta'- DNA-dependent RNA 
polymerase catalyzes the transcription 
of DNA into RNA using the four 
ribonucleoside triphosphates as 
substrates 




Phthiocerol synthesis polyketide 
synthase type I PpsC- involved in the 
elongation of either C22-24 fatty acids 
by the addition of malonyl-CoA and 
 209 
Rv1567c;deaD;cobU;Rv2949c methylmalonyl-CoA extender units to 









PE-PGRS family protein- mediates 
Ca(2+)-dependent up-regulation of the 
anti- inflammatory cytokine IL-10; 
Apoptosis inhibitor- effector protein 
that participates in the suppression of 
macrophage apoptosis by blocking the 
extrinsic pathway 
35 9 birA N 1 2 2 ethA;rrs;cobU;alr;PE_PGRS61
-Rv3654c;Rv1830;nrdF2-
Rv3049c;Rv1405c 
Possible bifunctional protein: biotin 
operon repressor and biotin--[acetyl-
CoA-carboxylase] synthetase 















Uncharacterized PPE family protein 
31 18 vapB3
5-
N 1 3 5 rrs;ispE;Rv0792c-
Rv0793;betP-
Antitoxin component of a type II toxin-







repressor- represses the transcription 
of mce3 operon and downregulates its 
own expression, but does not affect 












30 8 rpoA Y 1 2 2 eccA1;Rv1566c-
Rv1567c;Rv1830;alr;Rv1405c;
PE_PGRS61-Rv3654c;nrdF2-
DNA-directed RNA polymerase subunit 
alpha- DNA-dependent RNA 
polymerase catalyzes the transcription 
 212 
Rv3049c of DNA into RNA using the four 
ribonucleoside triphosphates as 
substrates 





that modifies short-chain fatty acids. 
In vitro, catalyzes the transfer of the 
methyl group from S- adenosyl-L-
methionine (SAM) to the double bond 
of phospholipid- linked oleic acid to 
produce tuberculostearic acid (10- 
methylstearic-acid or TSA) 




27 5 uvrD1 N 1 2 2 Rv0042c;Rv2897c;rrs;gnd2 ATP-dependent DNA helicase- DNA-
dependent ATPase, acting on dsDNA 
with a 3'-ssDNA tail, unwinding with 
3'-to 5'-polarity. A minimal tail of 18 nt 
is required for activity. Also highly 
efficient on nicked DNA. Involved in 
the post-incision events of nucleotide 
excision repair, as well as in 
nitrosative and oxidative stress 
response and possibly in persistence 
in the host. Inhibits RecA-mediated 
 214 
DNA strand exchange 
26 7 alr Y 1 2 2 rrs;birA;rpoA;PE_PGRS61-
Rv3654c;nrdF2-
Rv3049c;Rv1405c 
Alanine racemase; Catalyzes the 
interconversion of L-alanine and D- 
alanine. D-alanine plays a key role in 
peptidoglycan cross- linking 
26 10 Rv292
3c 









N 1 2 3 embB;lysX;umaA;ethA;echA1
0;rpoB;carB;Rv1482c-fabG1 
Sulfolipid-1 exporter- required for the 
biosynthesis and the transport across 
the inner membrane of sulfolipid-1 
(SL-1), which is a major cell wall lipid 










Uncharacterized protein  
21 8 Rv183
0 
N 1 2 2 eccA1;rrs;ethA;rpoA;birA;PE_
PGRS61-Rv3654c;Rv1405c 
Uncharacterized HTH-type 
transcriptional regulator  








18 6 eccA1 N 1 2 2 Rv1830;rpoA;PPE13;PE_PGRS
61-Rv3654c;Rv1405c 
ESX-1 secretion system protein- EccA1 
exhibits ATPase activity and may 




N 1 2 2 rrs;Rv2897c;gnd2 Sensor-like histidine kinase- probably 
forms part of a two-component 
regulatory system senX3/regX3. 
Phosphorylates regX3 (Probable); 
Sensory transduction protein regX3- 
probably forms part of a two-
 217 
component regulatory system 
regX3/senX3 





manno-heptose 1,7- bisphosphate 
intermediate into D-glycero-alpha-D-
manno-heptose 1- phosphate by 
removing the phosphate group at the 
C-7 position 
17 6 mce1D N 1 2 2 Rv0575c;echA10;pepE;PPE37;
Rv1507c 
Mce-family protein 




monooxygenase; Possible cationic 




N 1 2 2 rrs;PPE37 Uncharacterized protein 
13 3 Rv004
2c 




N 2 2.5 3 ispE;Rv1482c-
fabG1;pncA;rpoB;embB 
Uncharacterized MFS-type 
transporter, similar to many antibiotic 
and drug efflux proteins 
11 1 fadE1 N 1 1 1 NA Probable acyl-CoA dehydrogenase 






N 1 1 1 NA Probable conserved lipoprotein, 
possibly peptidase similar to many 
peptidases 
10 1 cysE N 1 1 1 NA Serine acetyltransferase- catalyzes the 
acetylation of serine by acetyl-CoA to 
produce O-acetylserine (OAS) 
10 1 dppB N 1 1 1 NA Probable dipeptide-transport integral 
membrane protein ABC-transporter 
(see citation below), similar to many 
peptide permeases  
10 1 lppC N 1 1 1 NA Putative lipoprotein LppC- probably 
involved in bacterial recognition and 
uptake by its host 
 220 
10 1 lppF N 1 1 1 NA Probable conserved lipoprotein 
10 1 mbtI N 1 1 1 NA Salicylate synthase- involved in the 





N 1 1 1 NA GTP 3',8-cyclase 1- catalyzes the 
cyclization of GTP to (8S)-3',8-cyclo-
7,8- dihydroguanosine 5'-triphosphate 
10 1 rpiB N 1 1 1 NA Ribose-5-phosphate isomerase B- 
catalyzes the interconversion of 
ribulose-5-P and ribose-5-P 
10 1 Rv045
8 




N 1 1 1 NA Uncharacterized glycosidase, possible 
conserved exported protein 
10 1 Rv374
0c 




N 1 1 1 NA Possible oxidoreductase, probably 
combines with product of 
downstream ORF MTV025.090c to 
form a functional monooxygenase; 
Probable cation-transporting P-type 
ATPase 
9 1 aceE N 1 1 1 NA Pyruvate dehydrogenase E1 
component 







N 2 2 2 Rv1482c-fabG1;carB Putative cytochrome P450 141; 




N 1 1 1 NA Deoxyguanosinetriphosphate 
triphosphohydrolase-like protein;  




N 1 1 1 NA ESX-1 secretion system protein - 
EccCb1 may link the cytosolic 
components of the system with the 
membrane components; PE family 
 223 
immunomodulator- plays a major role 
in RD1-associated pathogenesis, and 
may contribute to the establishment 
and maintenance of M.tuberculosis 
infection. Together with PPE68, 
stimulates the secretion of IL-10 and 
MCP-1 from human macrophages, via 
the interaction with human Toll-like 
receptor 2 (TLR2) 
9 1 mce1B N 1 1 1 NA Mce-family protein 
9 3 Rv030
2 
N 1 2 2 Rv1507c;gmhB Probable transcription regulatory 
protein, TetR family 





N 1 1 1 NA UPF0678 fatty acid-binding protein-
like protein, may play a role in the 




N 1 1 1 NA Uncharacterized protein 





carboxylase beta chain 4 
8 1 lprI N 1 1 1 NA Lipoprotein- strongly binds and 
inhibits lysozyme, may help bacteria 
 225 




N 1 1 1 NA Transcriptional regulatory protein- 
acts as a positive transcriptional 
regulator of the molybdopterin 
biosynthesis moa1 locus, promoting 
the expression of the moaA1B1C1D1 
genes. Binds directly to the moaA1 





N 2 3 4 rpoA;Rv0145;Rv1507A-
Rv1508c;ppsC;Rv1823;Rv057
5c;hycE-Rv0088 







N 1 1 1 NA Uncharacterized protein; UvrABC 
system protein B- the UvrABC repair 
system catalyzes the recognition and 
processing of DNA lesions 
8 1 Rv363
9c 
N 1 1 1 NA Uncharacterized protein 
8 1 snoP N 1 1 1 NA Pyridoxal 5'-phosphate synthase 
subunit- catalyzes the hydrolysis of 
glutamine to glutamate and ammonia 
as part of the biosynthesis of pyridoxal 
5'-phosphate. The resulting ammonia 
molecule is channeled to the active 
 227 
site of PdxS 
7 1 ftsH N 1 1 1 NA ATP-dependent zinc metalloprotease 
FtsH; Acts as a processive, ATP-
dependent zinc metallopeptidase for 
both cytoplasmic and membrane 
proteins. Plays a role in the quality 
control of integral membrane proteins 
7 1 katG-
furA 
N 1 1 1 NA Catalase-peroxidase; Bifunctional 
enzyme with both catalase and broad- 
spectrum peroxidase activity, oxidizing 
various electron donors including 
NADP(H). Protects M.tuberculosis 
 228 
against toxic reactive oxygen species 
(ROS) including hydrogen peroxide as 
well as organic peroxides and thus 
contributes to its survival within host 
macrophages by countering the 
phagocyte oxidative burst; 
Transcriptional regulator- represses 
transcription of the catalase-
peroxidase gene katG and its own 
transcription by binding to the 
promoter region in a redox-dependent 
manner 




heme/flavin oxidoreductase MftD; 
Putative mycofactocin system 




N 1 1 1 NA Conserved protein 
7 1 Rv030
8 
N 1 1 1 NA Probable conserved integral 
membrane protein, with C-terminus 
highly similar to C-terminus of other 




N 1 1 1 NA Possible bifunctional enzyme, 
including 2-hydroxyhepta-2,4-diene-
 230 




N 1 1 1 NA GTP cyclohydrolase 1 type 2 homolog; 
6 1 Rv028
1 




N 1 1 1 NA Uncharacterized protein Rv1366; 
Rv1366, (MTCY02B10.30), len: 273 aa. 
Hypothetical unknown protein 
6 1 Rv201
3 
N 1 1 1 NA Transposase 
6 1 Rv302
3c 




N 1 1 1 NA Ribosome-recycling factor- 
responsible for the release of 
ribosomes from messenger RNA at the 
termination of protein biosynthesis. 
May increase the efficiency of 
translation by recycling ribosomes 
from one round of translation to 
another; Uridylate kinase- catalyzes 
the reversible phosphorylation of 





















N 1 1 1 NA  Probable transcriptional regulatory 
protein; Uncharacterized protein 
1 1 cyp13
8 
N 1 1 1 NA Putative cytochrome P450 138 
 233 
1 1 dhaA N 5 5 5 Rv1507A-
Rv1508c;Rv0575c;hycE-
Rv0088;Rv1823 
Haloalkane dehalogenase 3- catalyzes 
hydrolytic cleavage of carbon-halogen 
bonds in halogenated aliphatic 
compounds 
1 1 espB N 1 1 1 NA ESX-1 secretion-associated protein- 
required for host-cell death and may 
support an EsxA- independent 
virulence function. Secreted processed 
form of EspB binds to phosphatidic 
acid and phosphatidylserine. Inhibits 
IFN-gamma-induced autophagy in 
murine macrophages 
 234 
1 1 fadE28 N 2 2 2 Rv2434c Acyl-CoA dehydrogenase- involved in 
the third cycle of side chain 
dehydrogenation in the beta-oxidation 
of cholesterol catabolism. May play an 
important role for the initial 
macrophage invasion, possibly in 
response to the acidification of 
phagosome. It contributes partly to 
the virulence by increasing the 




N 1 1 1 NA Cyclopropane mycolic acid synthase. 
Cyclopropanated mycolic acids are key 
factors participating in cell envelope 
 235 
1 permeability, host immunomodulation 
and persistence; Mycolic acid 
methyltransferase 
1 1 PE16 N 1 1 1 NA Member of the Mycobacterium 
tuberculosis PE family of proteins 
1 1 pks16-
pth 
N 2 2 2 hycE-Rv0088 Putative ligase; Peptidyl-tRNA 
hydrolase- the natural substrate for 
this enzyme may be peptidyl- tRNAs 
which drop off the ribosome during 
protein synthesis; Belongs to the PTH 
family 
1 1 rskA N 2 2 2 Rv1482c-fabG1 An anti-sigma factor for 
extracytoplasmic function (ECF) sigma 
 236 
factor SigK. ECF sigma factors are held 
in an inactive form by an anti-sigma 
factor until released by regulated 
intramembrane proteolysis (RIP) 
1 1 Rv005
2 









N 1 1 1 NA Probable proline dehydrogenase 
1 1 Rv305 N 1 1 1 NA Probable oxidoreductase, probably 
 237 
7c short-chain alcohol 
dehydrogenase/reductase 
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Table 3 





























ligase- catalyzes the activation of 
long-chain fatty acids as acyl-
adenylates 










DNA-directed RNA polymerase 
subunit beta-DNA-dependent 
RNA polymerase catalyzes the 
transcription of DNA into RNA 
using the four ribonucleoside 
triphosphates as substrates 
166 77 Rv205
9 























PE-PGRS family protein 













M.tuberculosis against toxic 
reactive oxygen species (ROS) 
including hydrogen peroxide as 
well as organic peroxides and 
thus contributes to its survival 
within host macrophages by 
countering the phagocyte 




















Putative antitoxin VapB34- 
antitoxin component of a 
possible type II toxin- antitoxin 
(TA) system 


















regulator involved in the 
repression of the 
monooxygenase EthA which is 
responsible of the formation of 
the active metabolite of 
ethionamide (ETH) 
  244 


















Uncharacterized protein; Redox- 
and pH-responsive 
transcriptional regulator, leads 
to respiratory alterations and 
bioenergetic deficiencies that 





negatively impact virulence 





Ribosomal RNA 16S 





catalyzes the deamidation of 
nicotinamide (NAM) into 
nicotinate 












regulatory protein, belongs to 
























reductase FabG1- catalyzes the 
NADPH-dependent reduction of 
beta- ketoacyl-ACP substrates to 
beta-hydroxyacyl-ACP products, 
the first reductive step in the 
elongation cycle of fatty acid 
biosynthesis 
83 44 lppC N 1 3 5 Rv1353c;vapB34;drrA;Rv3848;Rv131
3c;fadD30;Rv2075c-
Putative lipoprotein, probably 
involved in bacterial recognition 


















Probable cation efflux system 
protein 
79 37 fbiC N 1 3 5 Rv2059;fpg;Rv0158;Rv2024c-
Rv2025c;gca-
FO synthase 















71 31 PE23 N 1 2 4 Rv0158;Rv1353c;Rv2024c-
Rv2025c;fadD30;gyrB;vapB34;rrs;gca
-
Uncharacterized PE family 
protein 















glycosylase 1, involved in base 
excision repair of DNA damaged 
by oxidation or by mutagenic 
agents 
















67 29 PPE19 N 2 3 5 katG;Rv0123-
PE_PGRS2;embB;Rv2644c-
valT;rpoB;plsB1;rrs;Rv1482c-
Uncharacterized PPE family 
protein 























amidase CwlM- cell-wall 
hydrolase that hydrolyzes the 
amide bond between N-
acetylmuramic acid and L-
  253 
Rv2076c;Rv3848 alanine in cell-wall glycopeptides 
65 36 vapC2
5 






Ribonuclease VapC25- toxic 
component of a type II toxin-









Probable transposase for 
insertion sequence element 
IS1557 












Member of the Mycobacterium 
tuberculosis PE family, PGRS 
subfamily of gly-rich proteins 









removing enzyme- modifies, by 
uridylylation and 
deuridylylation, the PII 
regulatory protein (GlnB), in 
response to the nitrogen status 
  255 
of the cell that GlnD senses 
through the glutamine level 
56 33 PE_PG
RS32 







PE-PGRS family protein  
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55 22 Rv113
5A 

















Uncharacterized protein;  tRNA-
Val, anticodon cac 
35 16 drrA Y 1 2 4 ethA-
ethR;lppC;vapB34;Rv3736;Rv2024c-
Doxorubicin resistance ATP-
binding protein- part of the ABC 





transporter complex DrrABC 




N 2 3 4 embB;Rv1482c-fabG1;rpoB;Rv0123-
PE_PGRS2;rrs;katG;PPE19 
Probable DNA methylase 





DNA gyrase subunit B 
34 18 Rv197
9c 
N 2 3 4 Rv3736;Rv3415c-
whiB3;Rv3915;Rv2059;Rv3848;glnD;
Uncharacterized transporter, 
probable amino-acid or 













Probable conserved integral 









binding protein A; Probable 




N 1 3 5 PE_PGRS32;glnD;Rv3179;Rv0158;fpg
;Rv3736;gca-
Endonuclease 8 1- involved in 
base excision repair of DNA 














25 15 rpsL Y 1 2 4 rpoB;pncA;embB;katG;plsB1;rrs;cob
K;Rv0123-PE_PGRS2;Rv1482c-fabG1 
30S ribosomal protein S12- with 
S4 and S5 plays an important 
role in translational accuracy 
23 7 embC-
embA 
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arabinosyltransferase A 




catalyzes the reduction of the 
macrocycle of precorrin- 6X into 
precorrin-6Y 
15 6 inhA Y 1 2 2 mmpL12-
Rv1523;pncA;embB;Rv1482c-
fabG1;rpoB 
Enoyl-ACP reductase of the type 
II fatty acid syntase (FAS-II) 
system, catalyzes the NADH-
dependent reduction of the 
double bond of 2-trans-enoyl-
[acyl-carrier protein], an 
essential step in the fatty acid 
elongation cycle of the FAS-II 






N 1 1 1 NA Probable acyl-CoA 




N 1 2 2 Rv3415c;ethA-ethR;mkl-
vapC6;PE_PGRS42;vapB34 
Conserved protein 
11 1 hisG N 1 1 1 NA ATP phosphoribosyltransferase 
11 1 mfd N 1 1 1 NA Transcription-repair-coupling 
factor- couples transcription and 
DNA repair by recognizing RNA 
  262 




N 1 1 1 NA Undecaprenyl-diphosphatase- 
catalyzes the dephosphorylation 
of undecaprenyl diphosphate 






N 1 1 1 NA Possible conserved membrane 
protein; Conserved protein 
10 1 echA2 N 1 1 1 NA Enoyl-CoA hydratase EchA2  
10 1 gabD1 N 1 1 1 NA Succinate-semialdehyde 
  263 
dehydrogenase 




forming protein, which is 
involved in efflux of copper 
across the outer membrane. 
Essential for copper resistance 
and maintenance of a low 
intracellular copper 
concentration 
10 1 mpt64 N 1 1 1 NA Immunogenic protein 
10 6 PE_PG
RS30 
N 1 2 3 PE_PGRS42;glnD;Rv3415c;Rv1135A;
hsp-nirB;Rv1945-lppG;fadD30 
PE-PGRS family protein- 
mediates suppression of 
proinflammatory immune 
  264 
response in macrophages via 
modulation of host cytokine 
response 
10 1 pirG N 1 1 1 NA Exported repetitive protein- 
surface-exposed protein 
required for multiplication and 
intracellular growth 
10 1 PPE66 N 1 1 1 NA Uncharacterized PPE family 
protein PPE66 
10 1 ppk2 N 1 1 1 NA Polyphosphate:GDP 
phosphotransferase- uses 
inorganic polyphosphate (polyP) 
as a donor to convert GDP to 
  265 
GTP and modulates nucleotide 
triphosphate synthesis catalyzed 
by the nucleoside diphosphate 
kinase (Ndk) in favor of GTP 
production over CTP or UTP 
10 1 Rv111
2 
N 1 1 1 NA Ribosome-binding ATPase, YchF- 
ATPase that binds to both the 
70S ribosome and the 50S 





N 1 1 1 NA Uncharacterized protein; HTH-
type transcriptional regulator 
PrpR- plays a key role in 
  266 
9c regulating expression of 
enzymes involved in the 
catabolism of short chain fatty 
acids (SCFA)  
10 1 Rv200
5c 
N 1 1 1 NA Universal stress protein family 








N 1 1 1 NA Putative Rieske 2Fe-2S iron-
sulfur protein 
9 1 plsC N 1 1 1 NA Possible transmembrane 
phospholipid biosynthesis 




N 1 1 1 NA Uncharacterized protein 
9 1 Rv044
3 
N 1 1 1 NA Conserved protein 
9 1 Rv058
5c 




N 1 1 1 NA Uncharacterized protein 
9 1 Rv255
4c 
N 1 1 1 NA Putative pre-16S rRNA nuclease- 
could be a nuclease involved in 
processing of the 5'-end of pre-
16S rRNA 
  268 
9 5 smc N 1 2 3 gyrB;glnD;Rv3415c-whiB3;fadD30 Chromosome partition protein 
Smc- required for chromosome 
condensation and partitioning 
9 1 ureG N 1 1 1 NA Urease accessory protein UreG- 
facilitates the functional 
incorporation of the urease 
nickel metallocenter 
8 1 adhA N 1 1 1 NA Probable adhA,alcohol 
dehydrogenase 
8 1 aspS N 1 1 1 NA Aspartyl-tRNA synthetase with 
relaxed tRNA specificity since it 
is able to aspartylate not only its 
cognate tRNA(Asp) but also 





N 1 1 1 NA Member of the Mycobacterium 
tuberculosis PE family; 




N 1 1 1 NA Ribonuclease- toxic component 





N 1 1 1 NA Ribonuclease VapC29- toxic 
component of a type II toxin-
antitoxin (TA) system 
7 1 fadD2 N 1 1 1 NA Putative fatty-acid--CoA ligase  
  270 
1 
7 1 mbtB N 1 1 1 NA Phenyloxazoline synthase, 
involved in the initial steps of 




N 1 2 2 Rv3510c;Rv3415c Probable ribonucleotide 
transport ATP-binding protein; 
Toxic component of a type II 
type II toxin-antitoxin (TA) 
system, an RNase 
7 1 mscL N 1 1 1 NA Large-conductance 
mechanosensitive channel- 
channel that opens in response 
  271 
to stretch forces in the 
membrane lipid bilayer 
7 1 Rv010
6 
N 1 1 1 NA Uncharacterized protein 
7 1 Rv045
8 












N 1 1 1 NA Uncharacterized protein; 
Uncharacterized protein 




N 1 1 1 NA  Possible transcriptional 
regulator, highly similar in part 
to PSR proteins (penicillin 
binding protein repressors) 
7 5 Rv391
0 
N 2 3 5 glnA3;Rv0158;fbiC;Rv3415c-
whiB3;fpg;PE_PGRS42;Rv3848 
Probable peptidoglycan 
biosynthesis protein MviN 
5 4 gca-
gmhA 
N 1 2.5 3 Rv2464c;PE23;vapB34;fbiC Possible GDP-mannose 4,6-
dehydratase; Phosphoheptose 
isomerase 
4 1 lysS N 1 1 1 NA Lysine--tRNA ligase 1 
4 1 Rv372
2c 
N 1 1 1 NA Conserved protein 











N 3 3 3 Rv1135A;Rv3736;Rv2075c-Rv2076c Putative mycofactocin 
biosynthesis glycosyltransferase, 
MftF 
2 2 mcr7 N 2 2.5 3 embB;rpoB;katG Putative small regulatory RNA 
2 2 Rv202
8c 





N 3 3 3 fadD30;Rv3415c-whiB3 HTH-type transcriptional 
regulator- positively regulates 
the expression of at least 
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groEL2; Uncharacterized protein 
1 1 eccE2 N 3 3 3 katG;rpoB ESX-2 secretion system protein  
1 1 ethA Y 1 1 1 NA FAD-containing monooxygenase  
1 1 glnQ N 1 1 1 NA Probable glutamine-transport 




N 2 2 2 drrA Enoyl-ACP reductase of the type 
II fatty acid syntase (FAS-II) 
system, catalyzes the NADH-
dependent reduction of the 
double bond of 2-trans-enoyl-
[acyl-carrier protein], an 
essential step in the fatty acid 
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elongation cycle of the FAS-II 
pathway; Ferrochelatase- 
involved in the biosynthesis of 
heme 
1 1 lipR N 1 1 1 NA Putative acetyl-hydrolase- 
required for maintaining the 
appropriate mycolic acid 
composition and permeability of 




N 1 1 1 NA Probable conserved lipoprotein; 
hypoxanthine-guanine 
phosphoribosyltransferase 




N 1 1 1 NA 4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase 2- 
catalyzes the conversion of 1-
hydroxy-2-methyl-2-(E)- butenyl 
4-diphosphate (HMBPP) into a 
mixture of isopentenyl 







N 2 2 2 vapB34 3-methyl-2-oxobutanoate 
hydroxymethyltransferase- 
catalyzes the reversible reaction 
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ketoisovalerate to form 
ketopantoate; Conserved 
protein 
1 1 parE1 N 2 2 2 lppC  Toxic component of a type II 
toxin-antitoxin (TA) system 
1 1 phoR N 1 1 1 NA Possible two component system 
response phosphate sensor 
kinase membrane-associated 
1 1 PPE61 N 2 2 2 rpoB Uncharacterized PPE family 
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-
PPE62 
protein; Member of the 





N 1 1 1 NA Phosphatidylserine 
decarboxylase proenzyme- 






catalyzes the insertion of 
molybdate into adenylated 
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molybdopterin with the 




N 1 1 1 NA DNA-directed RNA polymerase 
subunit beta- DNA-dependent 
RNA polymerase catalyzes the 
transcription of DNA into RNA 
using the four ribonucleoside 
triphosphates as substrates; 
Neutral ceramidase- catalyzes 
the cleavage of the N-acyl 
linkage of the ceramides (Cers) 
to yield sphingosine (Sph) and 
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N 2 2 2 Rv3848 Uncharacterized protein; 
Transcriptional regulator- a 
transcription factor that is 
probably redox- responsive, 
probably plays a role in 
immunomodulation and 
reactivation after chronic 
infection. Its induction results in 
transcription of a number of 
  281 
genes including sigM, and the 
genes for 2 type VII secretion 





N 1 1 1 NA Uncharacterized protein; 
Multidrug efflux ATP-
binding/permease protein- 
overexpression in M. smegmatis 
increases resistance to 
erythromycin, ampicillin, 
novobiocin and vancomycin. It 
also reduces accumulation of 
ethidium bromide in the cell. 
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1 1 Rv025
8c 














N 1 1 1 NA Uncharacterized protein 
1 1 Rv068
1 
N 3 3 3 Rv2075c-Rv2076c;Rv2219 Probable transcriptional 
regulatory protein (Possibly 
TetR-family) 




N 1 1 1 NA Possible conserved integral 
membrane protein; Probable 




N 1 1 1 NA Probable conserved Pro-, Gly-, 
Val-rich secreted protein; 
Glyceraldehyde-3-phosphate 
dehydrogenase- catalyzes the 
oxidative phosphorylation of 
glyceraldehyde 3-phosphate 
(G3P) to 1,3-
bisphosphoglycerate (BPG) using 
the cofactor NAD 
1 1 Rv188 N 3 3 3 Rv0123-PE_PGRS2;katG Uncharacterized protein; 








N 3 3 3 hsp-nirB;PE_PGRS30 Uncharacterized protein; 
Possible conserved lipoprotein 
1 1 Rv207
4 
N 4 4 4 plsB1;embB;rrs F420H(2)-dependent biliverdin 
reductase- catalyzes the 
F420H(2)-dependent reduction 
of biliverdin-IXalpha at C10 
position, leading to bilirubin-
IXalpha, a potent antioxidant. As 
biliverdin-IXalpha is produced in 
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high amounts in macrophages 
infected with M.tuberculosis, its 
reduction by Rv2074 may play a 
role in protecting mycobacteria 
against oxidative stress, aiding 




N 1 1 1 NA Probable oxidoreductase 
1 1 Rv221
9 
N 3 3 3 Rv2075c-Rv2076c;Rv0681 Uncharacterized protein 
1 1 Rv261
6 
N 1 1 1 NA Conserved protein 
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1 1 Rv263
3c 
N 1 1 1 NA Uncharacterized protein 
1 1 Rv280
9 





N 2 2 2 Rv3415c Possible phosphatase; 
Conserved hypothetical protein 
1 1 typA-
lpqW 
N 2 2 2 drrA GTP-binding translation 
elongation factor; Probable 
monoacyl phosphatidylinositol 
tetramannoside-binding protein 
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Supplementary Table 1 
Phenotype Frequencies by lineage 
 
Lineage Drug-resistant MDR Pan-
Susceptible 
XDR 
2 469 1546 1399 155 
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Discussion 
The work in this thesis has utilised three distinct analysis technologies to explore 
the relationship between the Mtb genome and the development of drug resistance. 
Due to the clonal nature and distinct lineages of Mtb, I hypothesised that the 
specific genomic background would influence the specific mutations that develop in 
response to therapy; and that as a result, lineage specific GWAS, or LCS techniques 
would be more revealing of the genetic causes of resistance (and spread) than 
traditional approaches. Thus, my work provides; methodological insights regarding 
the GWAS, phyC and LCS methodologies, biological insights gained through their 
application, and implications for surveillance, diagnosis and treatment of 
tuberculosis and beyond.  
 
Methodological Insights 
Differences in the loci identified between each methodology demonstrates the 
complementarity between GWAS, phyC and LCS; there is utility in each approach 
(see Chapters 2-5). PhyC relies on independent evolution events and, as expected, 
appears more suited to highly diverse Mtb genomic datasets, considering all 
lineages together (see Chapter 2). On the other hand, GWAS is better able to 
identify lineage-specific associations with drug resistance (see Chapters 2 and 3). In 
such cases, there may be a higher relative importance of transmission than multiple 
independent evolution events. This might be expected when variants are highly 
transmissible; hence, GWAS may be a powerful tool in identifying variants 
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associated with highly transmissible resistant strains, as further indicated in 
Chapter 3. It is feasible that high transmissibility could coevolve with drug 
resistance. This is because more transmissible strains would likely experience more 
drug therapy and thus greater selection for resistance (see Chapter 3).  
It is less clear how LCS deals with structure in Mtb populations, as LCS takes an 
evolutionary approach to machine learning and thus a less structured approach to 
lineage diversity that may not be enhanced by controlling for lineage. Despite this, 
the importance of lineage background is revealed by its identification of lineage 
specific loci (see Chapters 4 and 5).   
While both phyC and GWAS approaches identify single variants or loci associated 
with a phenotype, LCS can identify patterns of one or more loci predictive of 
phenotype. This means LCS has the potential to discover epistatic relationships 
where GWAS and phyC do not (see Chapters 4 and 5). 
Here GWAS and phyC have been applied to both loci and genomic variants (SNPs 
and short indels) (see Chapters 2 and 3); conversely, due to computational 
intensity, LCS was applied only to locus-based genomic variants. The ability of LCS 
to make predictions from such lower resolution locus-based data may be due to the 
power increase resulting from simultaneous consideration of multiple loci (see 
Chapters 4 and 5). It is important to consider whether use of a binary locus-type, 
reference or non-reference, could introduce biases into LCS. For example, loci with 
a greater length may be generally more likely to have a non-synonymous mutation, 
and some loci may be able to withstand more non-synonymous variation with little 
effect on protein function. However, as computing power increases and there is 
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further algorithmic development, it would be interesting to apply LCS to SNP-level 
data. 
More generally, it is important to note that all three methodologies currently rely 
on mapping to a reference and thus introduce biases. This means that structural 
variation in the Mtb genome may be overlooked. 
All three methodologies could lead to predictions of resistance phenotype from 
Mtb genome. For GWAS and phyC this may be through variant discovery to inform 
a database of predictive variants within a predictor tool [1–8], whilst for LCS 
prediction is an inherent part of the algorithm and can be performed without the 
requirement of running the full learning algorithm [9]. 
 
Biological Insights 
The success of lineage-specific GWAS highlights potential differences in the 
genomics of drug resistance between lineages (see Chapters 2 and 3). Whilst some 
variants were identified by lineage-combined approaches, others were identified in 
only one lineage (see Chapters 2 and 3). Differences in evolutionary trajectory 
between lineages are compatible with recent evolution, since lineage divergence, 
as would be expected to result from selection pressures arising due to the 
introduction of antibiotics. Lineages 1 and 3 have the smallest sample sizes in the 
data analysed here, new larger datasets for these lineages could provide further 
insight here. 
Chapter 3 highlights the complexity of XDR Mtb, revealing a number of novel 
variants associated with the XDR phenotype. The application of LCS to XDR Mtb in 
Chapter 5 further delves into this complexity. Perhaps the ability of LCS to achieve 
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high accuracy of XDR prediction is due to its ability to deal with such complexity 
(see Chapter 5). Future work is required to determine the importance of selection 
compared to genetic drift in linking the loci identified to resistance phenotypes; 
nonetheless identifying such variants present in clinical XDR TB populations could 
inform public health response strategies (see Chapter 3). 
Loci identified in Chapter 2-5 warrant further investigation to unearth more detail 
on how they might functionally relate to resistance and transmission or fitness in 
general, especially those that lack knowledge at present. This demonstrates the 
utility of the GWAS, phyC and LCS methodologies in creating a more targeted 
approach to hypothesis generation for wet lab studies. 
 
Implications for Surveillance, Treatment and Diagnosis 
The GWAS, phyC and LCS as presented here (see Chapters 2-5) could have 
important implications for surveillance; as these approaches could be deployed to 
understand new clonal spreads of TB disease. As new whole genome sequence data 
is generated, it can be analysed to see if there are new genetic factors that are 
driving these outbreaks. This could be automated and facilitated through online 
Mtb monitoring systems that would enable precision public health, facilitating 
better allocation of resources and design of research strategies.  
In addition, the findings from the work presented can be used to improve the 
current online tools (such as TB-profiler) to give more accurate drug resistance 
predictions. 
However, it is important to consider feasibility of such proposals in light of growing 
Mtb genomic datasets and changing phenotypic methods [10]. For example, phyC 
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becomes increasingly difficult as datasets grow, due to limitations on phylogenetic 
tree construction. This indicates a need for new methods for tree construction or 
sampling of isolates from which to build trees. Similarly, as dataset size increases 
LCS may take longer to run. 
Furthermore, there are implications for diagnosis and treatment. Accurate 
prediction of resistance status from whole genome sequence can allow better 
selection of therapy regimens for individual patients without the need to wait for 
drugs susceptibility testing which can be lengthy. Moreover, an improved 
understanding of the biological mechanisms of resistance present in global Mtb 
populations could inform drug design.  
 
Future Avenues of Work 
There are a number of future avenues that could follow from this work. For 
example, the application of methodologies used here to new Mtb datasets; for 
example, using new genome sequencing methodologies such as long read methods  
[11], using datasets exploring within patient Mtb genomic diversity and exploring 
new phenotypes such as latent TB or further exploring drug resistance through MIC 
values. 
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Conclusions 
GWAS, phyC and LCS are complementary methodologies that can each provide 
insight into the genomic basis of drug resistance in Mtb and the prediction of drug 
resistance from the Mtb genome. This work proposes a number of loci as 
candidates for further study, that may be involved in drug resistance or in particular 
facilitate spread of drug resistant strains. This has important implications for 
surveillance, diagnosis and treatment of tuberculosis. 
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